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VIRTUAL CLINICAL TRIALS: ONE 
STEP FORWARD, TWO STEPS BACK 
LORI ANDREWS, KAYLA KOSTELECKY, STEPHANIE SPRITZ 
AND ALEXANDRA FRANCO 
 Virtual clinical trials have entered the medical research landscape. 
Today’s clinical trials recruit subjects online, obtain informed consent 
online, send treatments such as medications or devices to the subjects’ 
homes, and require subjects to record their responses online. Virtual 
clinical trials could be a way to democratize clinical research and 
circumvent geographical limitations by allowing access to clinical re-
search for people who live far from traditional medical research cen-
ters. But virtual clinical trials also depart dramatically from tradi-
tional medical research studies in ways that can harm individuals and 
the public at large. This article addresses the issues presented by vir-
tual clinical trials with regard to: (1) recruitment methods; (2) in-
formed consent; (3) confidentiality; (4) potential risks to the subjects; 
and (5) the safety and efficacy of treatments that are approved.  
I.  OVERVIEW 
Medical research on human beings has consisted of triumphs1 and trage-
dies.2  Like other human endeavors, medical research has been characterized by 
researchers’ capacity for brilliance and compassion at times, but also their baser 
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 1. See David Rose, A History of the March of Dimes, MARCH OF DIMES (Aug. 26, 2010), 
http://www.marchofdimes.org/mission/a-history-of-the-march-of-dimes.aspx (explaining that through the 
March of Dimes’ support, Salk’s research led to the breakthrough of a polio vaccine). 
 2. See The Tuskegee Timeline, CTRS. FOR DISEASE CONTROL AND PREVENTION, 
http://www.cdc.gov/tuskegee/timeline.htm (last visited Oct. 18, 2016) (chronicling the Tuskegee experi-
ments where black men with syphilis were not given treatment so that researchers could observe the nat-
ural course of the disease); see also, David S. Jones et al., Ethics and Clinical Research—The 50th Anni-
versary of Beecher’s Bombshell, 374 NEW ENG. J. MED. 2393, 2393–98 (2016) (arguing that “many 
interests—medical, personal, political, military and commercial—have led researchers to conduct studies 
they knew to be transgressive. It would be hubris to think that such lapses could not happen again”). 
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emotions of racism,3 sexism,4 and avarice.5  Legal rules—in particular the U.S. 
federal research regulations6—have been put into place to protect research par-
ticipants and to ensure that the treatments that are approved are safe and effec-
tive. 
But now ingenuity in another field—digital technology—is testing the abil-
ity of the research regulations to achieve their goals.7  Medical researchers have 
started to recruit research subjects based on their online searches,8 social media 
activities,9 and use of health apps.10 Rather than using an ad for a clinical trial in 
 
 3. See generally HARRIET WASHINGTON, MEDICAL APARTHEID: THE DARK HISTORY OF MEDICAL 
EXPERIMENTATION ON BLACK AMERICANS FROM COLONIAL TIMES TO THE PRESENT 157 (2006) (tracing 
systematic black oppression in medical science throughout American history and documenting abuse and 
lack of proper notification or consent in experimentation decades before Tuskegee). 
 4. Rebecca Dresser, Wanted: Single, White Male for Medical Research, 22 HASTINGS CTR. REP. 24, 
25 (1992) (explaining that women have been excluded from participation in biomedical studies due to 
perceived weakness, denying them the benefit of such research). 
 5. See Kurt Eichenwald & Gina Kolata, Drug Trials Hide Conflicts for Doctors, N.Y. TIMES (May 
16, 1999), http://www.nytimes.com/1999/05/16/business/drug-trials-hide-conflicts-for-doc-
tors.html?pagewanted=all&_r=0 (explaining that financial rewards caused doctors to place patients in re-
search studies that were not appropriate for them). 
 6. See 45 C.F.R. § 46 (2015); see also 21 C.F.R. § 50 (2016). 
 7. Zachary Brennan, Industry Calls for More Guidance From FDA on New Clinical Trials Tech-
nology, RAPS (May, 11 2016), http://www.raps.org/Regulatory-Focus/News/2016/05/11/24930/Indus-
try-Calls-for-More-Guidance-From-FDA-on-New-Clinical-Trials-Technology/. 
 8. E-Recruiting: Using Digital Platforms, Social Media, and Mobile Technologies to Improve Clin-
ical Trial Enrollment, INVENTIV HEALTH, 10 (Oct. 14, 2013), http://www.inventivhealth.com/docs/e-Re-
cruiting_Using_Digital_Platforms_Social_Media_and_Mobile_Technologies_to_Improve_Clini-
cal_Trial_Enrollment.pdf. 
 9. Id.; Maloyre Allison, Can Web 2.0 Reboot Clinical Trials?, 27 NATURE BIOTECH. 895, 897 
(2009) (detailing companies utilizing social media for clinical trial recruitment). 
 10. Roughly one-fifth of smartphone owners (nineteen percent) have health apps. Susannah Fox & 
Maeve Duggan, Tracking for Health, PEW RES. CTR.–PEW INTERNET & AMERICAN LIFE PROJECT, 
http://questromworld.bu.edu/grandchallenge/files/2013/03/PIP_TrackingforHealth_PDF, 11 (Jan. 28, 
2013) http://www.digitaltrends.com/mobile/google-play-store-2014-most-downloaded-apps/ [hereinafter 
Tracking for Health]. Industry estimates suggest that 50% of over 3.4 billion mobile device users will 
have downloaded a health app by 2018. FOOD AND DRUG ADMINISTRATION, MOBILE MEDICAL 
APPLICATIONS, http://www.fda.gov/medicaldevices/digitalhealth/mobilemedicalapplications/default.htm 
(last updated Sept. 22, 2015). Even game apps can collect information that is revealing about someone’s 
health. In some instances, the app or game or website is sponsored by a pharmaceutical company or bio-
technology company seeking information for research. Wayne Usher & James Skinner, Health Websites 
and Reliability Components, 55 ACHPER HEALTHY LIFESTYLES J. 29 (2008) (highlighting that websites 
can collect health information when the page is sponsored by a pharmaceutical company or biotechnology 
company seeking data for research); Micol Spinazzi, Human Behavior and the Health Information Search, 
MAKOVSKY HEALTH, (Apr.l 24, 2014), http://www.makovsky.com/insights/blogs/m-k-health/44-in-
sights/blogs/m-k-health/614-human-behavior-and-the-health-information-search (stating that for health 
information searches, mobile use is up thirteen percent, while PC use is down fourteen percent over the 
last year); Nicole May, Mobile Health Is App-le of Pharma’s Eye, PHARMAPHORUM.COM, (August 9, 
2013), http://pharmaphorum.com/views-and-analysis/mobile-health-is-app-le-of-pharma-s-eye/ (explain-
ing gamification of health apps could be focused on specific drugs or therapies); cf. Manhattan Research, 
Few Pharma Websites Optimized for Mobile, According to Manhattan Research’s New ePharma Com-
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a local newspaper or paying a physician up to $5,000 to convince her patients to 
participate in a clinical trial,11 the sponsor of a clinical trial can directly contact 
potential research participants based on their digital data, such as someone who 
did a Google search for “joint pain” or who “liked” the American Diabetes As-
sociation on Facebook.12  
This digital transformation has not only changed the practices of research-
ers, it has changed the mindset of potential subjects.  Clinical trial inquiries are 
one of the top online searches for health information.13  Online services such as 
TrialX—a free service that matches participants to relevant clinical trials based 
on their health information14—use Twitter15 to match potential research subjects 
to clinical trials that suit their needs: “all you need is to QuTweet (query tweets 
pronounced cue-tweets) us at TrialX (@trialx), put in the keyword ‘CT’ (for 
Clinical Trials) followed by your health profile.”16 
Clinical trial recruiters first used the web to recruit subjects into traditional 
research settings, asking the potential subject to travel to a university or research 
center to participate.17  But, in 2011, a fundamental change occurred.  The phar-
 
petitive Analysis Series, (Dec. 5, 2013), http://www.prnewswire.com/news-releases/few-pharma-web-
sites-optimized-for-mobile-according-to-manhattan-researchs-new-epharma-competitive-analysis-series-
234601981.html (foreshadowing a push by pharmaceutical companies into the health app space). For a 
listing of social media websites [and mobile apps] sponsored by pharmaceutical companies, see Mobile 
App Wiki, DOSE OF DIGITAL, http://www.doseofdigital.com/healthcare-pharma-mobile-app-wiki/ (last 
visited Sept. 28, 2016) (listing of mobile health applications sponsored by pharmaceutical companies); 
Social Media Wiki , DOSE OF DIGITAL, http://www.doseofdigital.com/healthcare-pharma-social-media-
wiki/ (last visited Sept. 28, 2016) (listing social media websites sponsored by pharmaceutical companies). 
 11. See Eichenwald & Kolata, supra note 5 (describing a recruitment effort in which Merck & Com-
pany offered a bonus to doctors who enrolled a quota of fourteen patients). 
 12. See generally Allison, supra note 9, at 900; cf. FRANK PASQUALE, THE BLACK BOX SOCIETY: 
THE SECRET ALGORITHMS THAT CONTROL MONEY AND INFORMATION 28 (2015) (describing how an in-
dividual who conducts an online search for information on a disease, then later completes a seemingly 
unrelated form, can land themselves on a targeted marketing list). 
 13. Allison, supra note 9, at 900. 
 14. Id.; see also Connecting Patients to Your Trials, TRIALX, http://trialx.com/iconnect/ (last visited 
Sept. 13, 2016) (explaining that patients can search TrialX for clinical trials related to a specific condition 
and contact the trial coordinator if they are interest in participating). 
 15. TrialX (@TrialX), TWITTER, https://twitter.com/trialx, (last accessed Sept. 7, 2016) (“Connect-
ing patients to clinical research via trial finders, mobile research apps and more.”). 
 16. Trialx, CROSSOVER HEALTHCARE (Apr. 9, 2009), https://crossoverhealth.word-
press.com/com/#comment-894. 
 17. See, e.g., E-Recruiting: Using Digital Platforms, Social Media, and Mobile Technologies to Im-
prove Clinical Trial Enrollment, supra note 8 (outlining practices for efficiently using social media to 
identify potential research participants, tailor clinical trial messages by using “patient speak,” and target 
potential participants); FRED HUTCHINSON CANCER RESEARCH CENTER, ACM NEWS, CLINICAL TRIALS 
NOW USING SOCIAL MEDIA TO ATTRACT TRIAL PARTICIPANTS, (Mar. 24, 2010), 
http://cacm.acm.org/news/80616-clinical- trials-now- using-social-media- to-attract- trial-partici-
pants/fulltext (describing the use of online advertisements to recruit participants for an HIV vaccine trial); 
ABOUT MYCLINICALTRIALLOCATOR.COM, MCTL, http://www.myclinicaltriallocator.com/about/ (last 
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maceutical company Pfizer received clearance from the Food and Drug Admin-
istration (FDA) to conduct a clinical trial entirely online.18  The Pfizer trial relied 
on a process for conducting clinical trials over the internet patented by Boston 
University19 and exclusively licensed to Mytrus, a clinical trials software com-
pany.20  Mytrus has since developed multiple technologies to support direct-to-
patient clinical trials, including an electronic informed consent system and re-
mote data collection mechanisms.21 
Online clinical trials were born of good intentions—to expand the opportu-
nities for both researchers and participants.22  Virtual clinical trials have already 
been conducted in which treatments have been tested, including for overactive 
bladder and osteoarthritis.23  The treatments include medications,24 devices,25 
and nutritional supplements.26 
 
visited Jan. 16, 2017) (explaining that the purpose of the website is to search for clinical trials in a specific 
geographic location). 
 18. Jennifer Corbett Dooren, A Clinical Drug Trial Via Phone, Computer, WALL ST. J. (June 7, 
2011), http://www.wsj.com/articles/SB10001424052702304432304576369840721708396. 
 19. U.S. Patent No. 7,251,609 (filed Apr. 28, 2000). 
 20. See Mytrus Secures Exclusive Rights to Clinical-Trials Patent from Boston University, MYTRUS 
(June 11, 2011), https://www.mytrus.com/en/news/detail/patent-rights; see also Mytrus Launches Pfizer 
Trial, MYTRUS (June 8, 2011), https://www.mytrus.com/en/news/detail/wsj-pfizer (explaining that Mytrus 
is supporting Pfizer’s study and holds the exclusive patent to conduct virtual clinical trials in the US). 
 21. MYTRUS, https://www.mytrus.com/en/products-services/direct-to-patient (last visited Jan. 15, 
2017). 
 22. See Deborah Covington & Kristin Veley, The Remote Patient-Centered Approach in Clinical 
Research, 24 APPLIED CLINICAL TRIALS 30, Feb./Mar. 2015 (explaining that online clinical trial can over-
come geographic obstacles and increase research efficiencies). 
 23. See Web-Based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Sub-
jects with Overactive Bladder (REMOTE), CLINICALTRIALS.GOV, https://clinicaltri-
als.gov/ct2/show/NCT01302938 (last visited Jan. 22, 2017) (conducting a remotely controlled exploratory 
clinical trial with internet based tools to study the effect of tolterodine on subjects with overactive blad-
der); see also Amp Orthopedics Initiates Clinical Trial in Knee Osteoarthritis Pain, MYTRUS (Dec. 7, 
2011), https://www.mytrus.com/en/news/detail/amportho-oa [hereinafter Amp Orthopedics] (conducting 
remote clinical study completely over a web-based medium to study the amelioration of knee pain in 
patients with mild to moderate Osteoarthritis using non-thermal Pulsed Radio Frequency treatment); see 
also Amp Orthopedics, Inc., Effectiveness Study of the Ivivi SofPulse for Pain Amelioration in Adults with 
Mild Knee Osteoarthritis, CLINICALTRIALS.GOV, https://clinicaltri-
als.gov/ct2/show/study/NCT01457742?term=Ivivi&rank=1 (last visited Jan. 22, 2017). 
 24. Web-Based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects 
with Overactive Bladder (REMOTE), supra note 23. 
 25. See Mytrus Ivivi Osteoarthritis Study, YOUTUBE.COM, (Aug. 7, 2013), 
https://www.youtube.com/watch?v=42-_lda9RLE (advertising the Mytrus Ivivi Osteoarthritis study to 
potential participants). 
 26. U.S. Patent No. 7,251,609 (filed Apr. 28, 2000). Timothy McAlindon et al., Effectiveness of Glu-
cosamine for Symptoms of Knee Osteoarthritis: Results from an Internet-Based Randomized Double-Blind 
Controlled Trial, 117 AM. J. MED. 643 (2004). 
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The characteristics of “virtual clinical trials”27 are that they: (1) identify 
potential participants by gathering data based on people’s online searches and 
activities; (2) determine if people qualify for a trial (sometimes based on a med-
ical record or X-ray, but sometimes based merely on the person’s self-report); 
(3) obtain the individual’s consent over the internet; (4) send the participant the 
treatment (drug or device) in the mail; (5) get the participant to report if the treat-
ment is working; (6) pay the participant at various points for participating; and 
(7) base the FDA approval and marketing decisions on those self-reports, or, in 
some cases, laboratory measures of progress.28 
This article examines virtual clinical trials in light of long-standing legal 
and ethical obligations of researchers.29  Federal regulations require researchers 
at institutions that receive federal funds to submit proposals for studies of human 
subjects to Institutional Review Boards (IRBs) that evaluate such proposals 
 
 27. Throughout this paper, we will refer to “virtual clinical trial(s)” or “online medical research” 
interchangeably when we are talking about the entirely remote clinical trials in which subjects are under-
going a clinical experiment at their home and over the internet. We will also use the terms “medical re-
search trial” and “clinical trial” interchangeably.  
 28. See Covington & Veley., supra note 22, at 31 (explaining that many aspects of clinical trials can 
be completed remotely, including recruitment, informed consent, reporting results, and payment); see also 
Amp Orthopedics, supra note 23 (requiring potential participants to submit an x-ray that indicates knee 
osteoarthritis to participate in the study); see also MYTRUS, Overactive Bladder Homepage, Sept. 24, 
2011, https://web.archive.org/web/20110924121322/https://oab.mytrus.com/home (last visited Jan. 16, 
2017 by searching for “oab.mytrus.com/home” in the Internet Archive’s Wayback Machine Index) (asking 
potential participants whether they experienced urine leakage); see also Miguel Orri et al., Web-based 
Trial to Evaluate the Efficacy and Safety of Tolterodine ER 4 mg in Participants with Overactive Bladder: 
REMOTE Trial, 38 CONTEMPORARY CLINICAL TRIALS 193 (2014) (explaining that Pfizer obtained a 
waiver from the FDA to ship the study drug to participants via overnight delivery); see also Frequently 
Asked Questions about the FDA Drug Approval Process, FDA (Jan. 7, 2015), 
http://www.fda.gov/Drugs/ResourcesForYou/SpecialFeatures/ucm279676.htm (last visited Sept. 14, 
2016) (explaining that clinical trials allow the FDA to decide whether a drug should be approved for 
marketing). 
 29. These duties include compliance with the Nuremberg Code, Federal Research Regulations, state 
research laws, and medical ethics codes.  NUERNBERG MILITARY TRIBUNALS VOL. II ,TRIALS OF WAR 
CRIMINALS BEFORE THE NUREMBERG MILITARY TRIBUNAL UNDER CONTROL COUNCIL LAW NO. 10 
181−82(U.S. Gov. Printing Office, Oct. 1946−Apr. 1949) (stating that basic principles must be met when 
experimenting with human participants to satisfy moral, ethical and legal concepts); see also DHHS Pro-
tection of Human Subjects, 45 C.F.R. § 46 (2015); see also CAL. HEALTH & SAFETY CODE § 24170 (West 
1978); see also, e.g., AMA Code of Medical Ethics, AM. MED. ASS., http://www.ama-
assn.org/ama/pub/physician-resources/medical-ethics/code-medical-ethics.page (last visited Jan. 16, 
2017) (stating that physicians must gain voluntary consent from the participant, disclose risks of the study, 
minimize any risks to the participant, and maintain confidentiality). 
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based on their adherence to federal regulations for the protection of human sub-
jects.30  The regulations provide that the risks to subjects be justified by the ben-
efits that may result from the research,31 that voluntary informed consent be gar-
nered,32 that confidentiality be maintained,33 and that vulnerable populations 
receive additional special protections.34  Furthermore, any research to be used in 
support of an application for drug approval to the FDA must comply with regu-
lations protecting human subjects in federally-funded trials, even if the research 
institutions do not receive federal grants.35  This expands the reach of the federal 
regulations to pharmaceutical and biotechnology companies planning to market 
new drugs and devices.36  The regulations are designed to protect research par-
ticipants from risks and to ensure that, when a treatment is marketed, it is safe 
and effective.37  
Virtual clinical trials could be a way to democratize clinical research and 
provide access to clinical research for people who live far from traditional med-
ical research centers by breaking down geographical barriers that hinder their 
participation.38  Such trials could also be more cost-effective than traditional re-
search which takes place at a hospital, university, or other medical institution.39  
But virtual clinical trials also depart dramatically from traditional medical re-
search studies.  This Article addresses several potential risks to the participants 
and to society: (1) inappropriate recruitment methods; (2) informed consent con-
cerns; (3) confidentiality issues; (4) potential risk to the subject; and (5) concerns 
about the safety and efficacy of treatments that are approved. The article also 
suggests ways in which these risks might be addressed through law.  
Consider the following scenario: a teenager is solicited over the internet, 
based on his social media comments or online searches, for a clinical trial of a 
treatment of depression. He poses as an adult, submits the informed consent form 
and is sent a six-week supply of pills. The sponsor adds money to his debit card 
each time he fills in a form about how he is feeling each day. Nothing could stop 
him from flushing the drugs down the toilet, saying the drugs are working, and 
collecting his money. In addition, since many companies collect data about peo-
ple’s activities on the web, the fact that he is in a depression research study could 
 
 30. 45 C.F.R. §§ 46.101(a), 46.102(h), 46.102(j), 46.103(b) (2015).  
 31. 45 C.F.R. § 46.111(a)(2) (2015).  
 32. Id. § 46.111(a)(4).  
 33. Id. at (a)(7).  
 34. 45 C.F.R. § 46.111(b) (2015). 
 35. See 21 C.F.R. § 50.1(a) (2016). 
 36. See id. 
 37. See 21 C.F.R. §§ 50.1(a) and 21 CFR § 99.201(a)(2) (2016). 
 38. See Covington & Veley, supra note 22, at 24. 
 39. See id. at 31. See Michael J. McFarland, Ethical Implications of Data Aggregation, SANTA 
CLARA U.: MARKKULA CTR. FOR APPLIED ETHICS (June, 1, 2012), https://www.scu.edu/ethics/focus-ar-
eas/internet-ethics/resources/ethical-implications-of-data-aggregation/. 
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be sold by data aggregators to third party institutions, such as employers and life 
insurers, and used to discriminate against him. In the meantime, the potentially 
dangerous drug could be approved based on “faked” data and a patient who takes 
the drug could be harmed.  
II.  HOW DO VIRTUAL CLINICAL TRIALS WORK? 
For a medical research trial to succeed, researchers must recruit and main-
tain an adequate number of participants for the duration of the study.40  An 
astounding 19.8 million participants were needed globally for clinical trials in 
2005; this figure has undoubtedly increased.41  As many as two-thirds of investi-
gative sites are unable to recruit a sufficient number of participants.42  In fact, 
one-third of investigative sites are unable to recruit even one participant.43 Even 
the National Cancer Institute has trouble enrolling patients for clinical trials; 
more than one in five trials it sponsored failed to enroll even one participant.44  
Fewer than 20% of trials meet their deadline; half of the delays are due to diffi-
culty recruiting participants.45 
This great demand for research participants reflects the increase in clinical 
research over the last twenty years, fueled in part by an increasing commercial 
interest in developing pharmaceutical products.46  At the same time, other forces 
 
 40. Trudo Lemmens & Paul B. Miller, The Human Subjects Trade: Ethical and Legal Issues Sur-
rounding Recruitment Incentives, 31 J.L. MED. & ETHICS 398, 400 (2003). 
 41. See VICKI ORANSKY WITTENSTEIN, FOR THE GOOD OF MANKIND?: THE SHAMEFUL HISTORY OF 
HUMAN MEDICAL EXPERIMENTATION 60 (Twenty-First Century Books, 2014) (stating that the number of 
participants needed for clinical trials rose from 2.8 million to 19.8 million between 1999 and 2005); cf. 
Trends, Charts, and Maps, CLINCALTRIALS.GOV, https://clinicaltrials.gov/ct2/resources/trends#Regis-
teredStudiesOverTime (last visited Jan. 16, 2017) (showing that the number of registered clinical trials 
rose from 24,921 to 207,083 between 2005 and 2015).  
 42. Press Release, Tufts Center for the Study of Drug Development, Drug Developers Actively Im-
proving Efficiency of Clinical Trials (Apr. 26, 2011), http://csdd.tufts.edu/news/com-
plete_story/rd_pr_apr_2011. 
 43. Allison, supra note 9, at 895.  
 44. Id. at 896. 
 45. Id. at 895. 
 46. Trudo, supra note 40. The top 15 pharmaceutical companies with the highest market earnings 
combined made approximately $526 billion in profits in 2014. See Tracy Staton, The Top 15 Pharma 
Companies by 2014 Revenue [hereinafter The Top 15], FIERCE PHARMA (Mar. 18, 2015), 
http://www.fiercepharma.com/special-report/top-15-pharma-companies-by-2014-revenue; see also Who 
Has the Biggest One? Sales of the Top Pharma Products by Revenue, PHARMACOMPASS (Apr. 23, 2015), 
http://www.pharmacompass.com/radio-compass-blog/who-has-the-biggest-one-sales-of-the-top-pharma-
products-by-revenue (explaining that THE TOP 15 calculated revenue based on every division within the 
companies analyzed, listing the following companies and their revenue in millions of dollars: Johnson & 
Johnson — 74,331; Novartis — 57,996; Roche — 47,462; Pfizer — 49,605; Sanofi — 43,070; Merck — 
42,237; GlaxoSmithKline — 39,960; AstraZeneca — 26,095; Bayer — 25,47; Gilead Science — 24,474; 
Teva — 20,270; Amgen — 20,063; AbbVie — 19,960; Eli Lilly — 19,615; Bristol Myers Squibb — 
15,879); see also Richard Anderson, Pharmaceutical Industry Gets High on Fat Profits, BBC NEWS 
(Nov. 6, 2014) (listing similar revenue numbers and estimating that the top companies have profit 
margins ranging from ten to forty-three percent.  
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deter people from participating in research.  The costs of participation, lack of 
insurance coverage for experimental treatments in clinical trials, and distrust 
arising as a result of past abuses of research subjects can deter enrollment in 
clinical trials.47  
This shortfall in participation is occurring at a time when people are in-
creasingly turning to online search engines to find health information. The 2015 
Rock Health Digital Health Consumer Survey found that 71 percent of adults in 
the United States have searched online for health information.48 The survey also 
found that 17 percent of the adult population is currently tracking a key health 
factor in a mobile application.49 
Drawing on the fact that people reveal their medical conditions on the web, 
researchers began to use that information to recruit research subjects.  In June 
2011, the pharmaceutical company Pfizer began the first virtual clinical trial in 
the U.S. under an investigational new drug application, with nearly every step of 
the trial—from candidate screening to data reporting—completed remotely.50  
The trial, Research on Electronic Monitoring of OAB [Overactive Bladder] 
Treatment Experience, or REMOTE, involved a drug that had already been ap-
proved by the Food and Drug Administration for that condition.51  
The goal was to recruit 600 participants for the REMOTE trial through tar-
geted advertisements that appeared when internet users entered certain words 
into search engines or social network sites and through banner advertisements on 
 
 47. See Paying for Clinical Trials, NIH, https://www.cancer.gov/about-cancer/treatment/clinical-tri-
als/paying (last updated June 22, 2016) (describing the costs involved with participating in a cancer clin-
ical trial); see also Janet Leah Richards, Geography is Destiny: Disparate Insurance Coverage for Cancer 
Clinical Trials Demands a Federal Mandate, 76 U. MO-K.C. L. REV. 141, 143, 144 (2007) (finding 
that insurance carriers use policy exclusions deny claims for experimental treatment); see also Osagie K. 
Obasogie, Prisoners as Human Subjects: A Closer Look at the Institute of Medicine’s Recommendations 
to Loosen Current Restrictions of Using Prisoners in Scientific Research, 6 STAN. J. C.R. & C.L. 41, 72–
73 (2010) (noting the changing landscape in clinical trials along with isolated incidents has drastically 
decreased public trust in clinical trials).  
 48. Malay Gandhi & Teresa Wang, Digital Health Consumer Adoption: 2015, ROCK HEALTH (2015), 
http://rockhealth.com/reports/digital-health-consumer-adoption-2015/#survey-overview. 
 49. Id.  
 50. See Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Sub-
jects with Overactive Bladder (REMOTE), supra note 23; see also Press Release, PFIZER, Pfizer Conducts 
First “Virtual” Clinical Trial Allowing Patients to Participate Regardless of Geography (June 7, 2011), 
http://press.pfizer.com/press-release/pfizer-conducts-first-virtual-clinical-trial-allowing-patients-partici-
pate-regardless. 
 51. See Hannah Waters, FDA Approval Signals More ‘Homework’ on the Horizon in Trials, 17 
NATURE MED. 754 (2011); see also Jennifer Ringler, Pfizer Asks Patients to Test Themselves, 
PHARMABLOG (June 14, 2011), http://iqpc-pharma.blogspot.com/2011/06/pfizer-asks-patients-to-test-
themselves.html (describing that REMOTE would use cell phone and internet access to recruit and track 
trial participants). Rachel E. Sherman, associate director for medical policy at the Center for Drug Evalu-
ation and Research stated that the main reason for the study was to test the methodology of virtual clinical 
trials.  See Mike Mitka, Strategies Sought for Reducing Cost, Improving Efficiency of Clinical Research, 
306 J. AM. MED. ASS’N, 364, 365 (2011) (providing a high level overview of the participant recruitment 
process mapped for the REMOTE trial by startup company Mytrus).  
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health websites.52  Those advertisements directed interested individuals to the 
trial’s website,53 which promised eligible participants $25 payments for each 
online assessment or lab visit, with the possibility of earning a maximum of 
$175.54  
The website, which was operated by the clinical trial software company 
Mytrus, screened potential participants through a two-part online questionnaire 
with basic questions such as, “Will you have access to the Internet for the next 
16 weeks (the study period)?” and “During the last 3 months: Have you leaked 
urine (even a small amount)?”55  After this initial questionnaire, researchers at-
tempted to verify a participant’s identity by asking questions that “only [the po-
tential participant] can answer” such as, “Select a street address you had in 
1985,” “Select a hospital in which you were born,” and “Select a model of car 
you owned in 1997,”56 and comparing the answers with public records data-
bases.57 
Upon completion of the initial part of the questionnaire, the website 
prompted the participant to review and sign an electronic informed consent doc-
ument with information about “the benefits and risks of the trial.”58  The in-
formed consent document also included what Mytrus calls a “friendly” question-
naire, but the inability to answer questions correctly would not necessarily 
preclude the person from participating in the study.59  
Next, Mytrus would contact the individual and send a package that included 
a debit card which would be filled with money after a participant completed 
“each study milestone” and lab supplies for a blood draw that could be conducted 
 
 52. CLINPAGE, Pfizer’s Web Experiment: No Site? No PI? No Problem, (Apr. 5, 2011), 
http://www.clinpage.com/article/no_site_no_pi_no_problem/C24. 
 53. Id.; see also MYTRUS, https://www.mytrus.com/ (last visited Jan. 22, 2017) (private company 
conducting recruitment).  
 54. Peter Mansell, Pfizer Announces ‘Virtual Clinical Trial Pilot in US, PHARMATIMES (June 9, 
2011), http://www.pharmatimes.com/news/pfizer_announces_virtual_clinical_trial_pilot_in_us_980906. 
 55. See Orri et al., supra note 28. (explaining how the web-based screening process worked during 
the trial); see also Association ELA, Mytrus 16-wk Paid Overactive Bladder Clinical Trial for Women, 
YOUTUBE at 1:07 (Apr. 2011), https://www.youtube.com/watch?v=Aya-
BYQyMQz8&list=PL1gonBvfnk1lEtILWBxAI0m9B7qTnyuNo&index=9 (describing the screening pro-
cess with example screening questions in a video designed to attract potential participants). 
 56. See Orri et al., supra note 28 (explaining that screening included precautionary procedures to 
confirm participant identities); Association ELA, supra note 55, at 1:15 (giving examples of questions 
that may be asked to confirm the participant’s identity). 
 57. Pfizer’s Web Experiment: No Site? No PI? No Problem, supra note 52. 
 58. See Association ELA, supra note 55, at 1:24–1:30 (explaining that the informed consent con-
tained information about the risks and benefits of the REMOTE trial); see also Orri et al., supra note 28, 
at 193 (describing the informed consent process for the REMOTE trial). 
 59. See, Mytrus, Inc., Mytrus Enroll Introduction, YOUTUBE (May 8, 2014), 
https://www.youtube.com/watch?v=1AqJWkYoOVs (advertising the Mytrus Enroll electronic informed 
consent product); see also Orri et al., supra note 28, at 191, 192 (explaining the informed consent process 
as it was conducted in the REMOTE trial). 
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either “during a home visit or at a nearby designated lab.”60  Mytrus would send 
the participants a digital diary device to “record urination volume and frequency 
of urinations throughout the study.”61  At the conclusion of the trial, participants 
received individual trial results for export into personal medical records.62  
Remarkably, during this process, participants receive a package containing 
enough of the drug to last 14 weeks without having to set foot inside a research 
facility.63  Because this methodology was unprecedented, Pfizer had to obtain a 
waiver from the FDA in order to send the drugs to the participants at their 
homes.64  
Other virtual clinical trials have been conducted using a similar methodol-
ogy.  One such trial tested the effectiveness of glucosamine and chondroitin sul-
fate in treating osteoarthritis.65  Researchers recruited participants through the 
internet using links on health-related internet sites, such as the Arthritis Founda-
tion’s webpage, and through advertisements in online publications unrelated to 
health.66  Similar to the REMOTE trial, a potential participant who  viewed the 
study website and indicated interest in participation would be screened over the 
internet by self-administered questionnaires.67  The screening questions in-
cluded: “Do you get pain in one or both knees after walking 2-3 city blocks (~1/4 
mile)?” and “Have you ever been diagnosed by a physician as having arthritis in 
your knees?”68  The glucosamine and chondroitin sulfate would then be sent di-
rectly to the participants’ homes and participants would record their reaction on 
an online form.69  
 
 60. See Association ELA, supra note 55, at 2:02–2:27 (describing the virtual overactive bladder clin-
ical trial to potential participants). 
 61. Id. at 2:55–3:05. 
 62. See Pfizer Press Release, supra note 51; see also Association ELA, supra note 55, at 2:40, 3:00-
3:05.  
 63. See Association ELA, supra note 55, at 2:36–2:46.  
 64. See Ringler, supra note 51 (reporting on Pfizer’s announcement of its new REMOTE clinical 
trial). One year after starting the REMOTE trial, Pfizer stopped enrolling subjects.  See Pfizer Ends Social 
Media Bid for Trial Recruitment, BIOSPACE (June 2012), http://www.biospace.com/News/pfizer-inc-
ends-social-media-bid-for-trial/264338.  Pfizer was ultimately not able to recruit enough people to partic-
ipate in the study.  See Nick Taylor, Pfizer Director Defends Virtual Trial After Recruitment Struggle, 
OUTSOURCING-PHARMA.COM (Mar. 6, 2012), http://www.outsourcing-pharma.com/Clinical-Develop-
ment/Pfizer-director-defends-virtual-trial-after-recruitment-struggle. 
 65. Tim McAlindon et al., Conducting Clinical Trials Over the Internet: Feasibility Study, 372 BMJ 
484, 484 (2003). 
 66. U.S. Patent No. 7,251,609 col. 18, l. 58–67 (filed Apr. 28, 2000); see also McAlindon et al., supra 
note 26, at 644.  
 67. U.S. Patent No. 7,251,609 col. 3, l. 3–15 (filed Apr. 28, 2000); see also McAlindon et al., supra 
note 65, at 485.  
 68. U.S. Patent No. 7,251,609 col. 19, l. 23–28 (filed Apr. 28, 2000); see also McAlindon et al., supra 
note 65, at 485. 
 69. U.S. Patent No. 7,251,609 col. 5, l. 47–60 (filed Apr. 28, 2000) (participants could also obtain 
the supplements at a pharmacy or clinic); see also McAlindon et al., supra note 65, at 485. 
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Devices, as well as drugs, have been mailed to research participants.  
Mytrus enrolled patients for a virtual clinical trial, sponsored by Ivivi Health 
Sciences, using an electromagnetic field therapy (EMF) device for the treatment 
of osteoarthritis.70  The device emitted a pulsed magnetic field to reduce inflam-
mation caused by osteoarthritis.71  The criteria for qualification in this study in-
cluded submission of an X-ray of each knee taken at least twelve months preced-
ing the study, self-reported constant knee pain in the two months preceding the 
study in at least one knee, the ability to read and complete survey questionnaires 
in English, and access to the internet on a daily basis.72  Mytrus’ website encour-
aged participation by exclaiming: “You’ll be glad to know we value your time.  
Patients who choose to participate in the study will sent a special debit card, that 
can be used anywhere that accepts normal debit cards.  You may earn up to $200, 
and payments will be automatically added to your card as you complete portions 
of the study.”73 
Mytrus collected information daily about how the participant was feeling 
using standard pain scales and questionnaires.74  Mytrus would ask participants 
questions such as: “How much knee pain are you experiencing today?” “Did you 
sleep well last night?” and “How difficult is it to walk up a flight of stairs?”75  
Mytrus finished the trial and anticipates that the results “could become the basis 
for market clearance” of the device.76  
Mytrus has expressed interest in conducting virtual clinical trials for binge 
eating, chronic obstructive pulmonary disease, diabetes, sleeping disorders and 
other maladies.77  In March 2016, Mytrus also announced that it would be provid-
ing the virtual trial infrastructure for the ADAPTABLE (Aspirin Dosing: A Pa-
 
 70. See Amp Orthopedics, supra note 23 (announcing a direct-to-patient clinic trial in knee osteoar-
thritis pain that allows patients to participate in the study from their own homes); see also id. (explaining 
that the purpose of the study is to evaluate the effectiveness of non-thermal pulsed radio frequency treat-
ment for alleviating knee pain in patients with mild to moderate osteoarthritis); Mytrus Ivivi Osteoarthritis 
Study, YOUTUBE (Aug. 7, 2013), https://www.youtube.com/watch?v=42-_lda9RLE (explaining the study 
to potential trial participants). 
 71. See Amp Orthopedics, supra note 23 (testing non-thermal pulsed radio frequency will be used 
for pain amelioration in adults with knee osteoarthritis); see also id (announcing a clinic trial that uses 
non-thermal pulsed radio frequency technology to alleviate pain from knee osteoarthritis.); Mytrus Ivivi 
Osteoarthritis Study, supra note 70, at 1:22. (explaining to potential participants that the study treatment 
is given through knee wrap devices). 
 72. Amp Orthopedics, supra note 23.  
 73. Mytrus Ivivi Osteoarthritis Study, supra note 70.  
 74. Id.  
 75. Id. at 4:00. 
 76. Amp Orthopedics, supra note 23.   
 77. Wouter Stomp, Pfizer Integrating Telemedicine into Clinical Trials, MEDGADGET (June 15, 
2011), http://www.medgadget.com/2011/06/pfizer-integrating-telemedicine-into-clinical-trials.html (not-
ing that Mytrus has trials slated for “osteoarthritis, binge eating, COPD, diabetes, sleep disorders and 
informed consent validation.”). 
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tient-Centric Trial Assessing Benefits and Long-Term Effectiveness) trial con-
ducted by the Duke Clinical Research Institute.78  The study plans to compare 
the dosing effects of aspirin in 20,000 subjects diagnosed with atherosclerotic 
cardiovascular disease.79  
The virtual clinical trials model is being embraced by pharmaceutical com-
panies, device companies, and even traditional research settings such as univer-
sities.80  But do the federal research regulations, drafted before the widespread 
use of the internet, adequately protect either subjects or the public when a virtual 
clinical trial is undertaken? 
III.  CONCERNS ABOUT ONLINE RECRUITMENT OF POTENTIAL RESEARCH 
SUBJECTS 
The federal research regulations provide little guidance about the recruit-
ment of research subjects, whether in traditional or virtual trials.81  When the 
regulations were enacted, it was expected that medical research subjects would 
be recruited by their physicians, who owed independent ethical and legal obliga-
tions to their patients.82 In that scenario, physician intermediaries had the duty of 
 
 78. PCORI, COMPARING TWO ASPIRIN DOSES TO PREVENT HEART ATTACK AND STROKES IN 
PEOPLE LIVING WITH HEART DISEASE: THE ADAPTABLE STUDY, https://www.pcori.org/research-re-
sults/2015/comparing-two-aspirin-doses-prevent-heart-attacks-and-strokes-people-living (last visited 
Feb. 16, 2017) (Trial website stating that as of January 2017, the trial’s status is “In Progress-Not yet 
recruiting”); see also, NIH, ASPIRIN DOSING: A PATIENT-CENTRIC TRIAL ASSESSING BENEFITS AND 
LONG-TERM EFFECTIVENESS (ADAPTABLE), https://wwwcf.nlm.nih.gov/hsr_project/view_hsrproj_rec-
ord.cfm?NLMUNIQUE_ID=20153384(National Institutes of Health website listing the ADAPTABLE 
trial’s status as “Ongoing”).   
 79. Mytrus Technology Chosen for Precedent-Setting ADAPTABLE Aspirin Trial, MYTRUS (Mar. 7, 
2016), https://www.mytrus.com/en/news/detail/20160307-dcri. 
 80. See Virtual Reality: Where Does the Clinical Trial Industry Go from Here?, CLINICAL TRIALS 
ARENA (Aug. 12, 2015), http://www.clinicaltrialsarena.com/news/operations/virtual-reality-where-does-
the-clinical-trial-industry-go-from-here-4644601 (noting that the pharmaceutical companies Pfizer, 
Sanofi, and Shire have each conducted at least one virtual clinical trial); see also Amp Orthopedics Initi-
ates Clinical Trial in Knee Osteoarthritis Pain, MYTRUS (Dec. 7, 2011), 
https://www.mytrus.com/en/news/detail/amportho-oa (explaining that medical device manufacturer Amp 
Orthopedics has conducted a virtual clinical trial for one of its products); see also Mytrus Technology 
Chosen for Precedent-Setting ADAPTABLE Aspirin Trial, supra note 79 (noting that Duke Clinical Re-
search Institute, an academic institution, is partaking in a virtual clinical trial).  
 81. Covington & Veley., supra note 22, at 24 (“There is little regulatory guidance on designing and 
conducting remote patient centered studies.”). 
 82. Clinical Trials and Human Subject Protection, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/default.htm, (last visited 
Feb. 20, 2018), (noting that regulations protecting human subjects in clinical trials have been in existence 
since the 1970s); see also AM. MED. ASS’N. CODE MED. ETHICS § 7 (2016) (noting ethical and legal ob-
ligations of physicians recruiting patients for clinical trials, and for the general presumption that it is phy-
sicians who recruit patients for clinical trials); Moore v. Regents of the Univ. of Cal., 793 P.2d 479, 483 
(Cal. 1990) (finding a legal cause of action when a physician who performed medical research on his 
patient without informed consent breached his fiduciary duty to the patient). 
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ensuring that participation in the trial was in the patient’s best interest83 and that 
the patient had the capacity to give informed consent.84  Even when a physician-
patient relationship did not exist between the potential subject and the recruiter, 
the clinical backgrounds of subject recruiters (such as nurses and doctors) en-
sured an awareness of the responsibility as medical professionals to protect indi-
vidual welfare.85  Although health care professionals (especially those paid to 
recruit patients into studies) did not always act in the patients’ best interests,86 
patients did have recourse to lawsuits based on malpractice,87 lack of informed 
consent88 or breach of fiduciary duty89 if the health care professional entered 
them into inappropriate and risky research. 
Online recruitment for clinical trials provides no such backstop to curtail 
inappropriate enrollment.  When trial recruitment occurs outside of the fiduciary 
relationship between physician and patient, the ethical imperative of acting con-
sistently with the patient’s best interest is removed.90  In place of a medical pro-
fessional with a well-established ethical duty to patient wellbeing, a question-
naire is responsible for safeguarding individual interests.91  Even the most 
beneficent questionnaire design will be crude in its assessment of patient best 
interests, as patient interests cannot be inferred from information about a pa-
tient’s online profile alone.  A patient who is harmed by enrollment in a study, 
or who has not provided informed consent, may have limited legal recourse when 
a trial is conducted virtually without the direct involvement of medical profes-
sionals.92  Legal causes of action that have traditionally protected trial partici-
 
 83. AM. MED. ASS’N. CODE MED. ETHICS § 7 (2016) (noting the ethical obligation to protect the 
participants’ interests). 
 84. See id. (requiring informed consent as an ethical obligation); see also A. D. Nieuw, Informed 
Consent, 12 MED. L. 125, 125–26 (1993) (noting that there is a legal duty to provide informed consent). 
 85. See Kurt Eichenwald & Gina Kolata, supra note 5 (emphasizing the responsibility that private-
practice doctors conducting research feel toward trial participants). 
 86. See id. (describing instances in which doctors with financial stakes in recruiting participants rec-
ommended patients for trials that were inappropriate for them, such as a patient who was referred despite 
a known heart condition that made him ineligible). 
 87. Karp v. Cooley, 493 F.2d 408, 423–24 (5th Cir. 1974) (noting in dicta the existence of a medical 
malpractice cause of action for experimentation).  
 88. Moore v. Regents of the Univ. of Cal., 793 P.2d 479, 483 (Cal. 1990) (finding a cause of action 
for performance of medical procedures without informed consent) 
 89. Id. 
 90. Id. (stating that when there is a physician-patient relationship, the physician is ethically bound to 
disclose “personal interests unrelated to the patient’s health” because of the fiduciary relationship). 
 91. Id. at 483 (declaring that medical professionals are bound by ethical duties, when a physician-
patient relationship exists); see also Covington & Veley, supra note 22 (describing how potential virtual 
clinical trial participants self-enroll online and submit trial data online, rather than through a doctor inter-
mediary). 
 92. Id. (requiring a physician-patient relationship before finding medical malpractice liability in the 
context of a clinical trial); see also Anthony Francis, Is This a Real Doctor-Patient Relationship?, 
  
202 JOURNAL OF HEALTH CARE LAW & POLICY [VOL. 19:189 
pants, such as breach of fiduciary duty or malpractice, are grounded in the par-
ticularities of the clinical relationship and professional norms.93  As the virtual 
trial is driven largely by private companies with no direct relationship to the pa-
tient, a harmed subject may be limited to causes of action such as breach of con-
tract.94  Unlike causes of action that emerged in response to power imbalances 
between patients and the medical establishment, contract law is likely to regard 
the patient as an autonomous party, ignoring the vulnerabilities of individuals 
who are ill, dependent on the expertise of others, and may be desperate for ther-
apeutic benefit.95  
There is little regulation of online recruitment and that which does exist is 
not focused on virtual clinical trials.96  The FDA has issued a guidance document 
about the recruitment of clinical trial subjects through an advertisement which 
“includes, but is not necessarily limited to: newspaper, radio, TV bulletin boards, 
posters, and flyers that are intended for prospective subjects.”97  According to 
the FDA guidance, advertising for clinical trial recruitment constitutes “the start 
of the informed consent and subject selection process.”98  The FDA requires that 
Institutional Review Boards review ads to ensure that they are not “unduly coer-
cive and [do] not promise a certainty of cure beyond what is outlined in the con-
sent and the protocol.”99  The FDA states that this requirement is particularly 
important when research “may involve subjects who are likely to be vulnerable 
 
MEDSCAPE (Mar. 1, 2012), http://www.medscape.com/viewarticle/759163 (explaining that while it is pos-
sible to form a physician-patient relationship online, it requires the physician to take an affirmative action 
to be involved in the patient’s medical care). 
 93. See Moore, 793 P.2d at 484 (finding a legal cause of action for a person who had been subjected 
to research without consent only because the participant had a physician-patient relationship with the re-
searcher). 
 94. See Mytrus And Pfizer Win Best Practices Award For Pioneering Work In Electronic Consent 
And Virtual Trials, MYTRUS (Feb. 10, 2014), https://www.mytrus.com/en/news/detail/20140211-scope-
award (awarding Mytrus and Pfizer, two private companies, for pioneering the clinical trial process); see 
also Covington & Veley, supra note 22 (describing virtual clinical trials with technology platforms that 
offer patient recruitment, consent, and data management, meaning the entire trial can be completed re-
motely via the internet); see also Covington & Veley, supra note 22 (describing virtual clinical trials with 
technology platforms that offer patient recruitment, consent, and data management, meaning the entire 
trial can be completed remotely via the internet); see also Grimes v. Kennedy Krieger Inst., Inc., 366 Md. 
29 (2001) (finding that informed consent agreements in nontherapeutic research projects can constitute 
contracts and create a special duty between participant and investigator). 
 95. Russell A. Hakes, Focusing On The Realities Of The Contracting Process—An Essential Step To 
Achieve Justice In Contract Enforcement, 12 DEL. L. REV. 95, 100–01 (2011) (explaining that contract 
theory assumes the freedom and autonomy of the actors when enforcing contracts, resulting in injustice 
when reality does not match this assumption).  
 96. See Recruiting Study Subjects—Information Sheet: Guidance for Institutional Review Boards and 
Clinical Investigators, FDA, http://www.fda.gov/RegulatoryInformation/Guidances/ucm126428.htm 
(last updated Jan. 25, 2016) (stating that advertising for clinical trials online requires “no additional safe-
guard” but fails to mention the regulation of a virtual trial). 
 97. Id. 
 98. Id. 
 99. Id. 
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to undue influence.”100  The guidance applies to online recruitment; however, it 
also states that IRB review of advertisements over the internet is not necessary if 
the advertisement displays limited information about the trial “such as the title; 
purpose of the study; protocol summary; basic eligibility criteria; study site lo-
cation(s) and how to contact the site for further information.”101 
The problem with the FDA’s approach is that it focuses on what is presented 
to the potential participant.102  As such, it pays no attention to how the potential 
participant came to be targeted to begin with.103  In traditional medical research, 
potential subjects were referred by their own physicians based on their actual 
medical conditions.104  In virtual clinical trials, people who may be on the inter-
net for wholly unrelated purposes are subjected to posts, banner ads, personal 
emails, and other tactics asking them to participate in research.105  This new ap-
proach—targeting based on what a person does on the internet—raises several 
problems.106  These include violation of privacy, exploitation of individuals who 
are vulnerable (or more likely to be “good” trial participants in terms of adher-
ence, not reporting adverse events, etc.) and coercion.107  
The web is a target-rich area for finding research subjects because people 
use the web in all aspects of their lives.108  They communicate with family mem-
bers and friends, seek information, schedule appointments and trips, and reveal 
personal, lifestyle, and medical information.109  Through their searches, pur-
chases, and posts, people reveal information about their medical conditions.110  
Health-related data can be analyzed from people’s general internet activities—
such as when they Google a particular ailment or medication, “like” a patients’ 
group such as a cancer society, or post unusual symptoms and request help from 
friends to identify the cause of the disease or condition.111  Health-related data 
 
 100. Id. 
 101. Id. 
 102. Id. (directing the IRB to review materials). 
 103. Id. 
 104. Joseph Walker, Data Mining to Recruit Sick People, WALL ST. J. (Dec. 17, 2013), 
http://www.wsj.com/articles/SB10001424052702303722104579240140554518458. 
 105. Id. 
 106. Id.; see also Brenda L. Curtis, Social Networking and Online Recruiting for HIV Research: Eth-
ical Challenges, 9 J. EMPIRICAL RES. HUM. RES. ETHICS 58, 58, 66 (Feb. 20, 2014), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316828/pdf/nihms576496.pdf. 
 107. See infra note 218–219.  
 108. Alicia Shelton, A Reasonable Expectation of Privacy Online: “Do Not Track” Legislation, 45 U. 
BALT. L.F. 35, 35, 38 (2014). 
 109. Id. LORI ANDREWS, I KNOW WHO YOU ARE AND I SAW WHAT YOU DID 2–3 (2012).  
 110. Shelton, supra note 108.  
 111. See Walker, supra note 104 (describing how health care companies are examining aggre-
gated data for clues about an individual’s health); see also Deborah Kogen, How Facebook Saved 
My Son’s Life, SLATE (Jul. 13, 2011), www.slate.com/id/2297933 (describing a mother whose son 
was diagnosed with a rare disease with the help of her friends after she posted her son’s symptoms 
on Facebook). 
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can also be gathered through medical and fitness apps (such as Fitbit)112 and 
through digital games designed to help patients deal with certain diseases (such 
as children with diabetes).113 
When a person posts something related to health on a social networking 
site, undertakes a web search for information about a particular disorder, or 
emails a health professional through Gmail, data aggregators and medical re-
searchers make assumptions about that person’s health and well-being.114  Med-
ical researchers sometimes use data about people’s web searches, “likes,” and 
health disclosures in private emails (such as over Gmail) to target potential re-
search subjects.115  
Online recruitment relies heavily on the collection and analysis of sensitive 
health information and other personal information that people may not even re-
alize they have revealed online.  Clinical trial recruiters are using patient com-
munity sites, social networks, behavior-specific and disease-oriented sites, and 
search engine queries about health behavior and medical conditions to identify 
potential research subjects.116  But researchers are also using online data unre-
lated to health to make inferences about people’s health status and then recruit 
them into studies.  If a person subscribes to premium cable TV and eats in fast-
food restaurants, he or she may be targeted for an obesity drug trial.117  According 
to Roger Smith, Senior Vice President at the data aggregation company Acurian, 
“We are now at a point where, based on your credit-card history, and whether 
 
 112. See FITBIT, FITBIT: CHARGEHR, http://www.fitbit.com/chargehr (the FitbitHR model of the fit-
ness tracker tracks heart rate in addition to other health metrics); see also Stephen Armstrong, What Hap-
pens to Data Gathered by Health and Wellness Apps?, BMJ (2016), http://www.bmj.com/con-
tent/353/bmj.i3406 (reporting that much of the data tracked by health and fitness apps like Fitbit are sold 
to third party companies).  
 113. See id. (reporting that much of the data tracked by health and fitness apps like Fitbit are sold to 
third party companies); see also Sarah R. Blenner et al., Privacy Policies of Android Diabetes Apps and 
Sharing of Health information, 315 JAMA 1051 (2016) (reporting the results of a study that found that 
diabetes apps often collected and shared sensitive health information with third parties). 
 114. See Lauren Solberg, Regulating Human Subjects Research in the Information Age: Data Mining 
on Social Networking Sites, 39 N. KY. L. REV. 327, 342–346 (2012) (stating that academic researchers are 
data mining social networking sites for biomedical, social, and behavioral research); see also Julia 
Angwin, The Web’s New Gold Mine: Your Secrets, WALL ST. J. (Jul. 30, 2010) http://online.wsj.com/ar-
ticle/SB10001424052748703940904575395073512989404.html (noting that website cookies and web 
beacons – tiny snippets of tracking code– allow companies to scan an individual’s browsing patterns and 
make assumptions about that individual’s income, shopping habits, and medical conditions); Google Pri-
vacy and Terms, GOOGLE, https://www.google.com/policies/terms/ (last visited Jan. 22, 2017) (stating 
that Google scans the content of emails to provide tailored advertising and other relevant product features). 
 115. See Walker, supra note 104; see also E-Recruiting: Using Digital Platforms, Social Media, and 
Mobile Technologies to Improve Clinical Trial Enrollment, supra note 8, at 10 (outlining how recruitment 
companies can monitor social media sites and discussion boards to improve recruitment methods and 
target potential participants); see also ANDREWS, supra note 109, at 45. 
 116. See E-Recruiting: Using Digital Platforms, Social Media, and Mobile Technologies to Improve 
Clinical Trial Enrollment, supra note 8, at 10 (Oct. 14, 2003) (explaining that targeted advertisements on 
digital platforms are a growing and effective way to recruit clinical trial participants).  
 117. Walker, supra note 104. 
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you drive an American automobile and several other lifestyle factors, we can get 
a very, very close bead on whether or not you have the disease state we’re look-
ing at.”118  Ken Shore, the Executive Vice President of Blue Chip (another data 
aggregation company like Acurian) explains that “[t]he types of magazines you 
buy, how often you buy running shorts, all of those things tell a story.”119 
When data aggregators obtain health data through online tracking mecha-
nisms, individual privacy protections are limited to the dictates of company pol-
icies, which generally strip information divulged online of any privacy protec-
tions.120  While some data aggregators claim to protect sensitive personal 
information, they adopt a definition of “sensitive” that fails to correspond to so-
cial expectations of privacy.121  Healthline Networks, Inc. places health-related 
advertisements on sites such as Dr. Oz, AARP,122 Ask.com, and U.S. News123 
based on the content of the page that the person is reading.124  Healthline claims 
that it does not allow advertisers to track sensitive health information such as 
HIV/AIDS, impotence, or eating disorders.125  However, it does permit tracking 
of other potentially stigmatizing conditions such as anxiety and bipolar disor-
der.126 
When data aggregators surreptitiously collect personal information about 
online activity, they invade privacy and disregard the integral role that online 
health resources play in today’s health care experience.  Online health resources 
may represent the only form of health care available to those who cannot afford 
a doctor or otherwise lack access to professional medical help, are too embar-
 
 118. Id. 
 119. Id. 
 120. See Sarah R. Blenner et al., supra note 113. (reporting the results of a study that found that dia-
betes apps often collected and shared sensitive health information with third parties). 
 121. See id. at 1053 (explaining that even apps with privacy policies commonly collect and share 
sensitive information with third parties). 
 122. Wade Roush, Healthline Battles WebMD with Personalized Medical Search Tools, Body Maps, 
XCONOMY (Nov. 30, 2011), http://www.xconomy.com/san-francisco/2011/11/30/healthline-battles-
webmd-with-personalized-medical-search-tools-and-3d-body-maps/#. 
 123. Healthline Networks Takes in $21M Series B, VENTUREWIRE (July 17, 2007), 
http://healthtools.aarp.org/corporate/news/Venture_Wire_HL_Networks_Takes_In_$21m.pdf (noting 
that Healthline secured distribution agreements to improve web site content for Aetna, AOL, Ask.com 
and U.S. News and World Report). 
 124. See Angwin, supra note 114 (explaining that targeted advertising is growing to meet demand for 
data on individual behavior and interests).  
 125. Id.   
 126. Id. 
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rassed to seek in-person treatment, struggle daily with chronic illness, or are dis-
satisfied with past treatment results.127  Thus, many people view divulgence of 
personal health information online as crucial to their personal welfare.128  
The chronically ill are more likely than those who are healthy to search 
online to learn more about medical conditions, such as depression or anxiety, as 
well as drugs, insurance, and investigational treatments.129  Therefore, these peo-
ple may have more data available for collection and are more likely to be solic-
ited for clinical trials.  According to a study by the Pew Research Center, the 
chronically ill are more likely than other people to seek information online about 
medical conditions, drugs and treatments, read drug and treatment reviews on the 
internet and gather information on the internet about another person’s health sit-
uation.130  Sixty-two percent of internet users with two or more chronic illnesses 
have looked online for information about a specific illness or problem.131  The 
chronically ill, especially the homebound, tend to be more reliant on the internet 
not only for health care information but also for social support.132 
Some research and clinical trial recruitment services create websites that 
provide medical information but may additionally or primarily exist to recruit 
research participants.  The clinical trial recruitment service MediGuard133 oper-
ates a website that offers to alert users about drug safety warnings and drug-drug 
interactions and provides users with information about side effects, safety alerts, 
 
 127. See Daniel J. Amante, Access to Care and Use of the Internet to Search for Health Information: 
Results From the US National Health Interview Survey, 17 J. MED. INTERNET RES. (2015), 
https://www.jmir.org/article/viewFile/jmir_v17i4e106/2 (reporting that people who lack access to care for 
various reasons are more likely to use the internet to search for health information); see also Magdalena 
Berger et al., Internet Use and Stigmatized Illness, 61 SOC. SCI. & MED. 1821, 1826 (2005) (describing a 
study that found that people with stigmatized illnesses are more likely to use the internet for health infor-
mation that those with non-stigmatized illnesses); Susannah Fox & Kristen Purcell, Chronic Disease and 
the Internet, PEW RES. CTR., 2 (Mar. 24, 2010), http://www.pewinternet.org/files/old-media//Files/Re-
ports/2010/PIP_Chronic_Disease_with_topline.pdf (noting that “internet users living with chronic disease 
are slightly more likely than other internet users to access health information online.”); Miriam McMullan, 
Patients Using the Internet to Obtain Health Information, 63 PATIENT EDUC. & COUNSELING 24, 26 
(2006) (describing a survey of cancer patients indicating that people who are dissatisfied with information 
provided to them by health professionals often turn to the internet for information). 
 128. Amante, supra note 127. (finding that more than 40% of adults use the internet to search for 
health information). 
 129. Fox & Purcell, supra note 127, at 2 and 17.  
 130. Susannah Fox & Maeve Duggan, Part One: Who Lives with Chronic Conditions, The Diagnosis 
Difference, PEW RES. CTR., at 2 (Nov. 26, 2013), http://www.pewinternet.org/2013/11/26 /part-one-who-
lives-with-chronic-conditions/. 
 131. Susannah Fox & Maeve Duggan, Part Two: Sources of Health Information, PEW RES. CTR., at 
14 (Nov. 26, 2013), http://www.pewinternet.org/2013/11/26/part-two-sources-of-health-information/. 
 132. Claire Cain Miller, Social Networks a Lifeline for the Chronically Ill, N.Y. TIMES, Mar. 25, 2010, 
at B3.  
 133. Patient Recruitment, QUINTILES, http://www.quintiles.com/services/patient-recruitment (last ac-
cessed Nov. 2, 2016) (advertising patient recruitment services on digital patient communities such as 
Mediguard.org). 
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recalls and a pill reminder app for smartphones134—but only after individuals 
provide information about their medical problems, drug allergies, medications, 
age, sex, race, and email address.135  While the site appears to offer a public 
service,136  MediGuard’s creator and CEO, Hugo Stephenson, says, “Our busi-
ness is identifying patients for clinical research projects.”137  As of May 2016, 
MediGuard had over 2.6 million members.138  
Researchers also advertise on more traditional social networks such as Fa-
cebook because it is easy for the researcher to target subjects and for Facebook 
users to share advertisements.139  Advertisements displayed on Facebook are 
placed according to users’ membership in condition-related groups, forums, or 
“likes,” and can be targeted according to gender, birthdate, and geographic loca-
tion (as precise as a specific city radius or ZIP code).140  The Acurian Facebook 
page, for example, shows an advertisement that reads: “Is asthma holding your 
child back? Enroll now in research studies offering up to $1500.”141  The adver-
tisement also gives Facebook users the option to “like” the ad, expanding its au-
dience by sending the information to others in their friend networks.142  As Acu-
rian notes, “because of the ‘viral’ character of social networks and activity, 
message reach can expand exponentially—without exponential investment.”143  
Social networks also allow recruiters to exploit social pressures to increase par-
ticipation.  Acurian encourages the use of social network site advertising because 
“social networks provide the potential for—and advantage of—peer-to-peer in-
fluence and referral.”144  Targeted advertising on Facebook has already been used 
 
 134. MEDIGUARD, https://www.MediGuard.org (last visited Nov. 2, 2016); Press Release, Quin-
tilesIMS, Patients Get Safety Information, Pill Reminders with New Mobile App from Quintiles, (Jan. 8, 
2014), http://www.quintiles.com/news/2014/01/patients-get-safety-information-pill-reminders-with-
new-mobile-app-from-quintiles (announcing MediGuard’s new app that functions as a pill reminder). 
 135. Privacy Notice for Website, MEDIGUARD, https://www.mediguard.org/help/what-is-iguard/pri-
vacy (last updated Dec. 2013) (explaining that users must provide “‘sensitive’” information such as “race 
and ethnicity, medicines, or health conditions of interest” to the site). 
 136. Allison, supra note 9, at 899; About Us, MEDIGUARD, https://www.mediguard.org/help/about_us  
(last updated Nov. 1, 2013) (noting MediGuard is also known as iGuard). 
 137. Allison, supra note 9, at 899.  
 138. MEDIGUARD, https://www.mediguard.org/ (last visited Feb. 16, 2017). 
 139. Michael Kosinski et al., Facebook as a Research Tool for the Social Sciences, 70 AM. 
PSYCHOLOGIST 543 (2015).  
 140. How to Target Facebook Ads, FACEBOOK BUS., https://www.facebook.com/business/a/online-
sales/ad-targeting-details (last visited Jan. 22, 2017). 
 141. AcurianHealth, FACEBOOK (Nov. 17, 2015), https://www.facebook.com/AcurianHealth/?fref=ts. 
 142. Id. 
 143. Scott Connor, Leveraging On-Line Social Networks for Clinical Trial Patient Recruitment, 
ACURIAN WHITEPAPER SERIES, at 2 (2010), http://www.clinicalleader.com/doc/social-media-for-patient-
recruitment-0001. 
 144. Id. 
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to reach young women for a sexual desire study145 and to recruit teenagers for a 
smoking cessation study.146 
Federal regulators have not amended research guidelines to address internet 
recruitment, even though internet recruitment creates unique risks.147  A person 
may be harmed psychologically when a research recruiter calls or emails and 
says, “Your Facebook profile indicates that you are at a high risk for an early 
heart attack.  Would you like to participate in a clinical trial to test a drug to avert 
heart disease?” He may be harmed if he is aggressively targeted for participation 
with promises of possible improvement and then denied admission to the trial 
because of eligibility criteria without explanation or an offer of other support 
services.  He may be physically harmed by the experimental drug sent to his 
home if the social media information or the Google searches do not actually re-
flect his health status.  In addition, if a drug is approved for widespread use be-
cause of a faulty diagnosis, it may be ineffective or even harmful to people who 
actually have the condition.  
People have complained about unsolicited research recruitment, but such 
complaints have not resulted in changes to the federal research regulations.148  A 
website called Complaints Board features some people’s experiences with re-
ceiving unsolicited mail from Acurian.149  One person commented: “I agree with 
complaint posted by person who received unsolicited mail from Acurian.  I also 
 
 145. Deborah Borfitz, A Social Approach to Patient Recruitment, BIO-IT WORLD (May 18, 2010), 
http://www.bio-itworld.com/BioIT_Article.aspx?id=98953. 
 146. Michelle A. Rait, et al., Recruitment of Adolescents for a Smoking Study: Use of Traditional 
Strategies and Social Media, 5 TRANSL. BEHAV. MED. 254 (2015) (recruited teenage substance abusers 
via social media).  
 147. See Covington & Veley, supra note 22 (commenting that there is little regulatory guidance for 
conducting a virtual clinical trial); see also U.S. DEPT. HEALTH & HUMAN SERV., SEC’Y’S ADVISORY 
COMM. ON HUMAN RESEARCH PROT., ATTACHMENT B: CONSIDERATIONS AND RECOMMENDATIONS 
CONCERNING INTERNET RESEARCH AND HUMAN SUBJECTS RESEARCH REGULATIONS (2013) (discussing 
how current human research regulations are outdated and do not address unique issues of internet re-
search). FDA guidance for recruiting study subjects only references the internet to note that IRB review 
and approval of listing of clinical trials on the internet is not required in most instances. See Recruiting 
Study Subjects—Information Sheet Guidance for Institutional Review Boards and Clinical Investigators, 
supra note 97. The U.S. Department of Health and Human Services, and fifteen other federal departments 
announced proposed revisions to modernize the federal policy for protection of human subjects in Sep-
tember 2015. Federal Policy for the Protection of Human Subjects, 80 FR 53931 (proposed September 8, 
2015). While the proposed rule addresses certain technological advances in human subject research, it 
does not address online recruitment of human subjects. Id at 53936–37. 
 148. See Recruiting Study Subjects—Information Sheet Guidance for Institutional Review Boards and 
Clinical Investigators, supra note 96 (explaining current regulations governing recruitment, which do not 
specifically address online recruitment); see also E-Recruiting: Using Digital Platforms, Social Media, 
and Mobile Technologies to Improve Clinical Trial Enrollment, supra note 8, at 10 (stating that there are 
no regulations that govern what media may be used to recruit human subjects). 
 149. Comments Forum to Acurian, Inc: Unsolicited Mail, COMPLAINTS BOARD, http://www.com-
plaintsboard.com/complaints/acurian-inc-pennsylvania-c574582.html (last updated Aug. 23, 2016). 
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received a letter.  Don’t have a clue as to where Acurian got my name and ad-
dress.  This can’t be legal. . . .”150  Another entry on the website reads: “My child 
just received a letter asking her to participate in a clinical study, she’s a minor!  
The only people who know of her disorder is her pediatrician and Walgreens 
pharmacy!!!  This can’t be legal!”151  Yet another comment states: “I worked in 
clinical trials for over 10 years and agree that trials are very important.  However, 
my son (a minor) received the same letter.  I have worked very hard safeguarding 
his medical diagnosis.  Outside of his doctor, pharmacy and school his name isn’t 
attached or listed on anything.”152  Others complained about receiving an invita-
tion from Acurian to participate in a clinical trial for a condition that they did not 
have, but had only researched on the internet.153  In fact, Acurian was the cause 
of over 500 Federal Trade Commission (“FTC”) complaints over a two-year pe-
riod, and has been sued because of its telemarketing practices.154 
Rather than expanding access to desperately needed experimental treat-
ments, as expected by early advocates of online clinical trial listings and online 
researchers, the internet may actually diminish opportunities for clinical trial par-
ticipation.155  Targeted exclusively at individuals fitting a particular profile, clin-
ical trial information will reach some eligible participants but not others.156  A 
person’s social media profile is likely to contain inaccuracies, or have little bear-
ing on medical eligibility, but it may nevertheless become the sole determinant 
of whether an individual is selected for clinical trial participation.157  Able to 
quickly and cheaply sort through thousands of potential clinical trial participants, 
the clinical trial industry can now exploit narrow selection criteria.158  Instead of 
contributing to the robustness of study design, online participant selection gives 
 
 150. L.N. Johnson, Comment to Acurian, Inc: Unsolicited Mail, COMPLAINTS BOARD (Jan. 5, 2012), 
http://www.complaintsboard.com/complaints/acurian-inc-pennsylvania-c574582.html. 
 151. Montezumas Mom, Comment to Acurian, Inc; Unsolicited Mail, COMPLAINTS BOARD, (June 14, 
2009), http://www.complaintsboard.com/complaints/acurian-inc-pennsylvania-c574582.html. 
 152. Keeping eyes open, Comment to Acurian, Inc; Unsolicited Mail, COMPLAINTS BOARD, (June 15, 
2013), http://www.complaintsboard.com/complaints/acurian-inc-pennsylvania-c574582.html. 
 153. See, e.g., Walker, supra note 104. 
 154. See id. (explaining how the FTC alleges that Acurian violated standard telemarking laws; how-
ever, the commission has not made comments on the current investigation as a matter of policy).  
 155. See text infra at notes 156–159.  
 156. See, e.g., E-Recruiting: Using Digital Platforms, Social Media, and Mobile Technologies to im-
prove Clinical Trial Enrollment, supra note 8 at 3, 8 (describing how e-recruiting on social media can 
target niche patient groups precisely).  
 157. Erica Naone, When Social Media Mining Gets It Wrong, MIT TECH. REV. (Aug. 9, 2011), 
https://www.technologyreview.com/s/424965/when-social-media-mining-gets-it-wrong/ (describing an 
experiment in which data mining misidentified a person two thirds of the time and concluding that a Fa-
cebook profile is not a reliable source of information); see also Chetan Khatri et al., Social Media and 
Internet Driven Study Recruitment, PLOS, at 2 (Mar. 16, 2015) (describing a study that evaluated the 
effectiveness of recruiting solely through social media and concluded that it was cost effective). 
 158. See, e.g., Walker, supra note 104 (explaining online recruiting companies can sort through thou-
sands of clinical trial participants and enroll larger numbers of patients in fast timeframes). 
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researchers the opportunity and means to favor the efficient and successful com-
pletion of product testing.159  Will a segment of “optimal” participants—perhaps 
characterized by a lack of assertiveness as to side effects, the absence of a support 
system to oversee the process, or the lack of access to affordable alternatives—
define the future of clinical trials?  
The online process for recruitment of clinical trial subjects not only threat-
ens the privacy of people’s medical information but also lacks the transparency 
that should be associated with medical or scientific research.160  Luring people 
to a website which promises to provide a free service to help manage a person’s 
condition when it instead exists primarily to collect and disclose people’s sensi-
tive health information is dishonest and unethical.161  When people turn to the 
online world to share medical information—for example, through social net-
works or patient support forums—they do so because they are seeking support 
for a medical condition or concern.162  An online forum post is the virtual equiv-
alent of a conversation in a physical support group, only more accessible.163  A 
person may believe that a computer screen will protect his or her identity and the 
privacy of his or her health information.164  Even if websites decide to engage in 
greater transparency and tell users up front whether they disclose their personal 
information to third parties, people should not have to decide between access to 
information and attempting to safeguard their privacy.165 
 
 159. See Mark Zetin & Cara T. Hoepner, Relevance of Exclusion Criteria in Antidepressant Clinical 
Trials, 27 J. CLINICAL PSYCHOPHARMACOLOGY 295, 300 (2007) (replicating and concurring with a study 
that found that exclusion criteria in antidepressant trials is being used to find particular participants that 
would produce ideal results for FDA marketing approval); see also, e.g., E-Recruiting: Using Digital 
Platforms, Social Media, and Mobile Technologies to improve Clinical Trial Enrollment, supra note 8, at 
3, 8 (advertising e-recruiting services capable of targeting precise groups of prospective subjects). 
 160. Allison, supra note 9, at 895, 899 (describing privacy concerns related to recruiting online and 
noting that some companies appear to offer free services to help people manage their medication without 
explaining that their business model is recruiting patients for clinical trials). 
 161. See id. at 899 (explaining how iGuard identifies patients for clinical research projects by offering 
free tools to manage medications).  
 162. See, e.g., Jam Kotenko, The Doctor Will See You Now: How The Internet and Social Media Are 
Changing Healthcare, DIGITAL TRENDS (Apr. 18, 2013), http://www.digitaltrends.com/social-media/the-
internet-and-healthcare (noting how people use Twitter, Tumblr, and Facebook as virtual support groups); 
see also Fox & Purcell, supra note 127 at 17, 20 (explaining how twenty-eight percent of internet users 
living with disease use the internet to research their symptoms or talk to other users to inquire about their 
experiences with the same disease). 
 163. Marsha White & Steve M. Dorman, Receiving Social Support Online: Implications for Health 
Education, 16 HEALTH & EDUC. RES. 693, 694 (2001) (explaining how online support groups offer many 
benefits like 24/7 access without having to leave home and anonymity).   
 164. See FTC Recommends Congress Require the Data Broker Industry to be More Transparent and 
Give Consumers Greater Control over Their Personal Information, FTC (May 27, 2014), 
https://www.ftc.gov/news-events/press-releases/2014/05/ftc-recommends-congress-require-data-broker-
industry-be-more (noting that many consumers are unaware that their data is being collected and sold). 
 165. See, e.g., INSTITUTE OF MEDICINE,  HEALTH DATA IN THE INFORMATION AGE: USE, DISCLOSURE, 
AND PRIVACY 17 (Molla S. Donaldson & Kathleen N. Lohr eds., 1994) (showing how consumers often 
feel compelled to consent to waivers or they will forego the benefit sought and how those same consumers 
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The vast amount of information that people knowingly, or sometimes inad-
vertently, reveal about themselves online creates benefits and risks in the health 
research context.166  On the positive side, researchers can contact potential sub-
jects directly, providing interested people with the opportunity to participate in 
research.167  On the negative side, the information that study participants provide 
online can be used by data aggregators in ways that disadvantage them.168  People 
may be upset by the invasion of privacy and may suffer psychological harm.169  
Moreover, the quality of the research may suffer due to this form of recruitment 
if the targeted research subject looks for health information for someone else 
online or if the researchers’ assumptions about the health status of consumers 
based on their purchases are wrong (such as when someone who purchases pre-
mium cable is not obese).170  
Targeted recruitment of clinical trial participants promises to increase 
awareness of relevant trials while relieving researchers of some of the burden of 
screening out the large percentage of interested individuals who are ultimately 
deemed ineligible.171  However, online recruitment based on information ac-
quired through non-transparent practices also threatens individual privacy rights, 
the well-being of participants, the integrity of the trial process, and ultimately the 
health of the public. 
 
are not informed of how their records will be used in the future); see also Privacy Notice for Website, 
supra note 135 (explaining how in order to receive services from MediGuard, customers must sign a 
waiver that allows MediGuard to collect sensitive information). 
 166. See Walker, supra note 104 (explaining how health researchers can now find individuals who 
would not show up through traditional profiling methods by using data information that they inadvertently 
disclose, like online purchasing habits, or knowingly disclose, like their demographics).  
 167. Connor, supra note 143, at 1 (explaining how social media sites like Facebook and Snapchat 
allow companies to place ads and trial information directly in front of potential subjects). 
 168. See, e.g., Walker, supra note 104 (explaining concerns that data may be used to deny employment 
or reveal illnesses that people would like to keep private); see also Angwin, supra note 114 (noting that 
there are no legal limits on how consumer data can be used).  
 169. See Michael McFarland, Why We Care about Privacy, MARKKULA CTR. FOR APPLIED ETHICS, 
https://www.scu.edu/ethics/focus-areas/internet-ethics/resources/why-we-care-about-privacy/ (last ac-
cessed Jan. 22, 2017) (explaining how people can be harmed or disadvantaged if their personal information 
becomes public). 
 170. See Walker, supra note 104 (explaining that Blue Chip Marketing found patients for an obesity 
drug by targeting people who subscribe to premium cable and frequent fast food dining, characteristics 
that suggest a sedentary lifestyle). 
 171. See Chetan Khatri et al., supra note 157, at 2 (noting that targeting on social media could reach 
new pools of interests subjects and lead to more efficient recruitment); see also e-Recruiting: Using Dig-
ital Platforms, Social Media, and Mobile Technologies to Improve Clinical Trial Enrollment, supra note 
8, at 2, 12 (describing targeted e-recruitment efforts which increased traffic to a trial website by about 
6,500% and another that tripled the number of patient’s recruited while reducing recruitment costs).  
  
212 JOURNAL OF HEALTH CARE LAW & POLICY [VOL. 19:189 
IV. EQUITABLE SELECTION IN RECRUITMENT 
Although the federal research regulations do not comprehensively address 
recruitment, they do require that the selection of subjects be “equitable.”172  This 
means that even if the requirement of informed, voluntary participation in re-
search is satisfied, doing research on a specific group of people if the research is 
intended to benefit another group would violate the federal regulations.173  For 
example, it would be inequitable to do research primarily on babies of color if a 
particular condition affects babies of all races, especially if the parents of white 
babies are more likely to afford treatments produced from such research.  Equally 
problematic is choosing a powerful group in society, such as men, and using 
them as subjects in research for a condition that affects both men and women, if 
the type of treatment developed will mainly benefit men.174  The federal research 
regulations state that in order to ensure equitable selection, Institutional Review 
Boards are required to consider the goals of the particular study, the setting in 
which it will be conducted, and the special concerns raised by vulnerable re-
search subjects such as children, prisoners and the disabled.175  
In the process of drafting the federal research regulations, a government 
commission analyzed the ethical concerns raised by research on humans in the 
Belmont Report.176  The Report states that justice requires “researchers to exhibit 
fairness: thus, they should not offer potentially beneficial research only to some 
patients who are in their favor or select only ‘undesirable’ persons for risky re-
search.”177  The Belmont Report also states that injustice in the recruitment of 
 
 172. 45 C.F.R. § 46.111(a)(3) (2015); 21 C.F.R. § 56.111 (a)(3) (2016). 
 173. See Equitable Selection of Participants, U. UTAH INSTITUTIONAL REV. BD., at 1, 
http://irb.utah.edu/_pdf/BMGS-EquitableSelectionofParticipants.pdf (last visited Jan. 22, 2017) (requir-
ing that benefits and burdens from research be distributed fairly); see also Belmont Report: Ethical Prin-
ciples and Guidelines for the Protection of Human Subjects of Research, 44 Fed. Reg. 23,192–93 (Apr. 
18, 1979) [hereinafter Belmont Report] (explaining how the distribution of benefits and burdens should 
be guided by the concept of justice). 
 174. See, e.g., Rebecca Dresser, Wanted Single, White Male for Medical Research, 22 HASTINGS CTR. 
REP. 24, at 24, 27 (Feb. 1992) (noting how male-only studies of heart disease and cholesterol led the 
American Heart Association to recommend a diet that could exacerbate the risk of heart disease among 
women); Karen H. Rothenberg, Gender Matters: Implications for Clinical Research and Women’s Health 
Care, 32 HOUS. L. REV. 1201, 1208 (1996) (describing how women were frequently left out of clinical 
trials for AIDS therapies); R. Alta Charo, Protecting Us to Death: Women, Pregnancy, and Clinical Trials, 
38 ST. LOUIS U. L.J. 135, 156 (1993) (stating that the exclusion of fertile women from research trials for 
the sake of protecting the women and their future offspring ultimately leads the FDA to authorize market-
ing of untested drugs to such women). 
 175. See 45 C.F.R. § 46.111(a)(3) (2015); see also 21 C.F.R. § 56.111(a)(3) (2016). 
 176. See THE NAT’L COMM’N FOR THE PROT. OF HUM. SUBJECTS OF BIOMED. & BEHAV. RES., THE 
BELMONT REPORT: ETHICAL PRINCIPLES AND GUIDELINES FOR THE PROTECTION OF HUMAN SUBJECTS 
OF RESEARCH (1979); see also Belmont Report, supra note 173, at 192–93 (Apr. 18, 1979) (providing a 
summary of the 1979 Belmont Report and noting the abuses of human subjects in biomedical experiments 
during World War II, which led to the Nuremberg code). 
 177. THE NAT’L COMM’N FOR THE PROT. OF HUM. SUBJECTS OF BIOMED. & BEHAV. RES., supra note 
176, at 6-1, 6-2; Belmont Report, supra note 173, at 196. 
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subjects may arise as a result of “social, racial, sexual and cultural biases insti-
tutionalized in society,” which may skew the distribution of risks and benefits of 
research.178  Although the report clarifies that it is not the researchers’ duty to 
correct institutionalized social injustices, it emphasizes that researchers can help 
by “consider[ing] distributive justice in selecting research subjects,” thus mini-
mizing the effect of social inequality.179 
Another concern raised by inequitable selection is sampling bias.180  Sam-
pling bias is an error introduced into the methodology of a particular research 
initiative by recruiting subjects who are not truly representative of the population 
that the sample is meant to study.181  As an example, a study to test the average 
bone density of women between the ages of 35 to 40 that recruits only women 
from a high-income urban neighborhood has a biased sample.182  Because 
women living in a wealthy, city neighborhood are likely to have both better ac-
cess to quality nutrition and more time to exercise than women of the same age 
living in a low-income neighborhood or in a rural area, the sample of recruited 
subjects is likely to skew the results of the study.183 
Equitable selection of subjects is not adequately protected in virtual clinical 
trials.184  At a basic level, the online platform is biased against people who are 
poorer, older, and live in rural areas.185  Virtual clinical trials exclude those who 
do not use the internet or those who do not own a computer or smartphone.186  If 
 
 178. Belmont Report, supra note 173, at 196. 
 179. See id. at 23,196–97; THE NAT’L COMM’N FOR THE PROT. OF HUM. SUBJECTS OF BIOMED. & 
BEHAV. RES., supra note 176, at 6-1, 6-2. 
 180. See Dresser, supra note 174, at 26–27 (stating that injustice in the selection of human subjects 
has contributed to imbalance in study populations). 
 181. See Elden Henson, A Pocket Guide to cGMP Sampling, INST. OF VALIDATION TECH., at 7–8 
(2006),http://www.ivtnetwork.com/sites/default/files/A%20Pocket%20Guide%20to%20cGMP%20Sam-
pling.pdf (providing the definition of sampling bias).  
 182. See Susan E. Parks et al., Differential Correlates of Physical Activity in Urban and Rural Adults 
of Various Socioeconomic Backgrounds in the United States, 57 J. EPIDEMIOLOGY & CMTY. HEALTH 29, 
34 (2003) (describing how lower income, rural residents were less likely than higher income, suburban 
residents to meet physical activity recommendations).  
 183. See id.; see also Access to Healthy Foods in Low-Income Neighborhoods,  RUDD CTR. FOR FOOD 
POL’Y & OBESITY, 6 (2008), http://www.ct.gov/dph/lib/dph/hems/nutrition/pdf/yale_rudd_center_ac-
cess_to_healthy_foods_report_2008.pdf (explaining that there are fewer supermarkets in low-income and 
rural areas, which makes access to healthy and affordable foods more difficult than individuals who are 
oppositely situated); Gina Shaw, Osteoporosis Tips: Build Stronger Bones, WEBMD (Jan. 14, 2011), 
http://www.webmd.com/osteoporosis/features/build-stronger-bones?page=3 (explaining how nutrition 
and exercise positively associate with greater bone density). 
 184. See Kathryn Zickuhr & Aaron Smith, Home Broadband 2013, PEW RES. CTR., 1, 3 (2013), 
http://www.pewinternet.org/files/old-media/Files/Reports/2013/PIP_Broadband%202013_082613.pdf 
(noting that only sixty-two percent of Americans living in rural areas, forty-three percent of those over 
the age of sixty-five, thirty-seven percent of people who did not graduate from high school, and fifty-four 
percent of those earning less than $30,000 per year have access to a fast internet connection).  
 185. Id. 
 186. See Kai Langel, Patient-Centric Engagement and the Digital Age, APPLIED CLINICAL TRIALS 
(Apr. 1, 2014), http://www.appliedclinicaltrialsonline.com/patient-centric-engagement-and-digital-age 
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the studies require extensive data collection through a computer, this may be 
more difficult for people with a slow internet connection.  Furthermore, if the 
study is limited to individuals using a more expensive smartphone (such as an 
iPhone), the research would only involve wealthier individuals.187  Currently, all 
three of these problems exist.  
A 2014 poll conducted by the Pew Research Center found that 13 percent 
of adults in America do not use the internet.188  Another study also conducted by 
the Pew Research Center found that although the use of the internet and owner-
ship of computers is prevalent in U.S. households, there are still disparities in the 
way internet connectivity is distributed across different geographic areas.189  The 
study found that, for example, in the Boulder metropolitan area approximately 
eight out of ten homes had access to a fast, broadband internet connection 
whereas in other metropolitan areas such as Harlingen, Texas, only approxi-
mately half of the homes have access to a fast internet connection.190  In general, 
approximately 30 percent of the U.S. population does not have access to a fast 
internet connection at home.191  The most affected groups include those who did 
not graduate from high school, people over the age of 65, those earning less than 
$30,000 per year, and those living in rural communities.192 
Inequitable internet access means that although computer use and internet 
access is prevalent in the U.S., some populations may not be easily accessible for 
recruitment or for participation in online medical research.193  If people in spe-
cific geographic areas are significantly less likely to turn to the internet for med-
ical information because they have no access to a fast internet connection, re-
searchers recruiting subjects based on their online searches would be less likely 
 
(noting how there is some bias in virtual clinical trials due to individuals who lack Internet access being 
unable to participate). 
 187. See Zickuhr & Smith, supra note 184, at 2, 6 (finding those with high income and educational 
attainment are much more likely to own iPhones). 
 188. See Susannah Fox & Lee Rainie, The Web at 25 in the U.S., PEW RES. CTR., 5 (Feb. 27, 2014), 
http://www.pewinternet.org/files/2014/02/PIP_25th-anniversary-of-the-Web_0227141.pdf (stating 87 
percent of adults use the internet). 
 189. Lee Rainie & D’Vera Cohn, Census: Computer Ownership, Internet Connection Varies Widely 
Across U.S., PEW RES CTR, (Sept. 19, 2014), http://www.pewresearch.org/fact-tank/2014/09/19/census-
computer-ownership-internet-connection-varies-widely-across-u-s/. 
 190. Id. 
 191. See Zickuhr & Smith, supra note 184, at 2 (Aug. 26, 2013), http://www.pewinternet.org/~/me-
dia//Files/Reports/2013/PIP_Broadband%202013_082613.pdf (finding 70 percent of the U.S. population 
has access to a high speed internet connection at home). 
 192. See id. at 3 (finding 62 percent of Americans living in rural areas, 43 percent of those over the 
age of 65, 37 percent of people who did not graduate from high school, and 54 percent pf those earning 
less than $30,000 per year have access to a fast internet connection). 
 193. See Amneris E. Luque et al., Barriers and Facilitators of Online Patient Portals to Personal 
Health Records Among Persons Living with HIV, 2 JMIR RES. PROTOCOL. 1, 6 (2013) (finding that inad-
equate internet access made access to online medical research more difficult.). 
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to recruit these people for studies.  Because historically disadvantaged popula-
tions often lack a fast internet connection, recruitment of subjects for clinical 
research that relies exclusively on an online framework would be inherently in-
equitable. 
For example, in online clinical research trials such as Pfizer’s REMOTE or 
Ivivi’s EMF trial, there were issues of equitable selection of subjects because the 
trials required subjects to have access to an internet connection.194  In online 
clinical trials, subjects complete informed consent forms online and constantly 
enter information on the trial’s website.195  For Ivivi’s Osteoarthritis EMF study 
it can take up to 20 minutes for the subjects to complete the required data forms 
online.196  Since the entire trial depends upon constant and reliable access to fast 
internet, the recruitment and enrollment of subjects for these trials would be in-
herently inequitable, disproportionately excluding disadvantaged populations 
such as the elderly or low-income earners.  
If a potential subject is required to have a high-end smartphone to partici-
pate, only wealthier individuals will have access to the clinical trials.  A 2013 
Pew Research Center poll revealed that 91 percent of adults own a cellphone197 
and 56 percent of cellphone users own a smartphone.198  Generally, research con-
ducted using smartphones presents problems of equitable subject selection.199  
People over the age of 65, people who did not graduate from high school, and 
those with an income lower than $30,000 per year are less likely to own a 
smartphone than the rest of the population.200 
Using the iPhone’s ResearchKit as the platform for virtual clinical trials 
presents even greater issues of equitable subject selection and sampling bias due 
to the difference in the demographics of people who use Apple’s iPhone instead 
of smartphones with other operating systems.  ResearchKit is an “open-source 
framework” which allows researchers to create medical apps to conduct research 
on iPhone users exclusively.201  By utilizing the iPhone’s internal instruments, 
 
 194. See Orri et. al., supra note 28, at 191 (stating that REMOTE trial participants were enrolled and 
managed entirely remotely through internet and mobile-phone platforms); see also Amp Orthopedics, su-
pra note 23 (listing daily access to the internet as one of the inclusion criteria). 
 195. Orri et al., supra note 28, at 191. 
 196. Mytrus Ivivi Osteoarthritis Study, supra note 70.  
 197. Lee Rainie, Cell Phone Ownership Hits 91% of Adults, PEW RES. CTR. (June 6, 2013), 
http://www.pewresearch.org/fact-tank/2013/06/06/cell-phone-ownership-hits-91-of-adults/. 
 198. Aaron Smith, Smartphone Ownership 2013; 56% of American Adults Are Now Smartphone Own-
ers,” PEW RES. CTR. (June 5, 2013), http://www.pewinternet.org/2013/06/05/smartphone-ownership-
2013/, at 2.   
 199. Id., at 3 (describing a study that found that only about half of Americans are smartphone owners 
and those who own smartphones tend to be educated and wealthy). 
 200. Id. at 3–4. 
 201. See ResearchKit and CareKit, APPLE, https://www.apple.com/researchkit/ (last visited Jan. 22, 
2017); see also ResearchKit for Developers, APPLE, https://developer.apple.com/researchkit/ (last visited 
Jan. 22, 2017). 
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such as the phone’s accelerometer and gyroscope, and by using the information 
collected from HealthKit—a set of apps which allow the user to enter health in-
formation and which also collect data passively—researchers can conduct stud-
ies on subjects remotely and collect metrics at any time of the day.202  Current 
ResearchKit initiatives include medical research studies on asthma, Parkinson’s 
disease, and diabetes.203  
The future of ResearchKit may also involve virtual clinical trials for phar-
maceutical companies.  In July 2015, GlaxoSmithKline announced that it was in 
the planning phases of using ResearchKit for drug research and development.204  
The pharmaceutical company behind the painkiller OxyContin, Purdue Pharma, 
also told reporters that it was exploring the possibility of using ResearchKit for 
drug research and development.205  Apple’s Senior Vice President of Operations 
said that the company would be open to for-profit efforts that are going to “make 
an impact on people’s health” and that this is the reason why Apple made Re-
searchKit an open-source platform.206 
According to a Pew Research Center poll conducted in 2013, 40 percent of 
people earning over $75,000 a year own an iPhone compared to only 13 percent 
of those who earn less than $30,000 per year.207  Also, while 38 percent of college 
graduate smartphone users own an iPhone, only 11 percent of smartphone users 
who did not graduate high school own one.208  The disparity in iPhone ownership 
is even greater in the African-American community, in which only 16 percent of 
smartphone users own an iPhone.209  
By conducting medical research exclusively on a narrow segment of the 
population, ResearchKit—and virtual clinical trials in general—presents issues 
of equitable selection as well as sampling bias.  The risks and benefits of research 
will not be distributed across a representative sample of the general population 
or even the general smartphone-owning population.  For example, people who 
 
 202. ResearchKit and CareKit, supra note 201; see also HealthKit, APPLE, https://developer.ap-
ple.com/healthkit/ (last visited Jan. 22, 2017) (stating that customers may provide permission for the app 
to passively collect data to be used in research). 
 203. ResearchKit and CareKit, supra note 201.  
 204. See Stephanie M. Lee, Big Pharma Eyes iPhone for Drug R&D, BUZZFEEDNEWS (last updated 
July 12, 2015, 1:31 PM), http://www.buzzfeed.com/stephaniemlee/big-pharma-eyes-apples-researchkit-
for-drug-development#.hfOa1GEnq; see also GSK, TWITTER (July 10, 2015, 1:56 PM) https://twit-
ter.com/GSK/status/619565807325048832; Can an iPhone Transform the Way we Monitor and Improve 
Patient Health?, GSK (July 8, 2016), http://us.gsk.com/en-us/behind-the-science/innovation/can-an-iph-
one-transform-the-way-we-monitor-and-improve-patient-health/.  
 205. See Lee, supra note 204 (“Purdue Pharma, the privately held, multibillion-dollar drug developer 
in Connecticut that’s best known for OxyContin painkillers, told BuzzFeed News that it’s in the early 
stages of exploring whether Apple’s new tool for research data collection can be used as part of its own 
drug R&D efforts.”).  
 206. Id. 
 207. Smith, supra note 198, at 7. 
 208. Id. 
 209. Id. 
  
2018] VIRTUAL CLINICAL TRIALS 217 
choose to participate in ResearchKit studies are not only likely to be representa-
tive of the average iPhone user demographic (high-income, college-educated in-
dividuals) but also include those who use the iPhone’s HealthKit to keep track 
of their calorie intake or step count.210  Any developments that result from the 
research—such as a new drug—will have been developed from a very narrow 
sample of people; as commentators point out, a section of the “richest 15 percent 
of the world”211 that is proactive about managing their conditions and improving 
their health.212 
At the same time, however, virtual clinical trials can test the most dangerous 
treatments on low-income and disadvantaged populations.  Researchers in the 
past have recruited vulnerable subjects and performed risky research on them.213  
For example, research sites have recruited homeless people214 and undocumented 
immigrants215 to participate in drug trials.  These participants enter the trial for 
the opportunity to earn desperately needed money.216  Researchers have failed to 
ensure that a participant is not simultaneously participating in several trials, 
which can affect the results of the studies.217  Virtual clinical trials create even 
more opportunities to target vulnerable populations.  Online behavioral market-
ing studies have demonstrated how to identify vulnerable, easy-to-manipulate 
 
 210. Id. (finding that more than three times as many iPhone users made over $75,000 per year, com-
pared to iPhone users who made less than $30,000 per year; and more than three times as many iPhone 
users were college-educated than did not graduate high-school); see also ResearchKit, APPLE, http://re-
searchkit.org/ (last visited Jan. 22, 2017) (“ResearchKit works seamlessly with HealthKit, researchers can 
access even more relevant data for their studies—like daily step counts, calorie use, and heart rate.”). 
 211. See Jim Edwards, The iPhone 6 Had Better Be Amazing and Cheap, Because Apple Is Losing the 
War to Android, BUS. INSIDER (May 31, 2014, 8:27 AM), http://www.businessinsider.com/iphone-v-an-
droid-market-share-2014-5 (explaining that the high price of Apple smartphones may be limiting its mar-
ket share to 15%). 
 212. See Arielle Duhaime-Ross, Apple’s New ResearchKit, THE VERGE (Mar. 10, 2015), 
http://www.theverge.com/2015/3/10/8177683/apple-research-kit-app-ethics-medical-research (explain-
ing that people who use ResearchKit are more likely to be engaged in monitoring and improving their 
health, and may not represent the entire population affected by the disease). 
 213. Susan Perry, Recruitment of Homeless People for Drug Trials Raises Serious Ethical Issues, U 
Bioethicist Says, MINNPOST, (Aug. 11, 2014), https://www.minnpost.com/second-opinion/2014/08/re-
cruitment-homeless-people-drug-trials-raises-serious-ethical-issues-u-bioet; see also, Carl Elliott, The 
Best-Selling, Billion-Dollar Pills Tested on Homeless People; How the Destitute and the Mentally Ill Are 
Being Used as Human Lab Rats, MATTER (July 28, 2014), https://medium.com/matter/did-big-pharma-
test-your-meds-on-homeless-people-a6d8d3fc7dfe#.eoz7mpmb2; David Evans, Michael Smith & Liz 
Willen, Big Pharma’s Shameful Secret, BLOOMBERG MKT, (Special Report, Dec. 2005), http://www.jour-
nalism.columbia.edu/system/documents/523/original/2006_Evans_Big_Pharma_s_Shameful_Se-
cret_MAG.pdf. 
 214. See Elliot, supra note 213 (stating that research organizations send employees to homeless shel-
ters to recruit patients). 
 215. See Evans et al., supra note 213, at 37–38, 42 (quoting an undocumented immigrant who volun-
teered as a patient to earn desperately-needed money for his family). 
 216. See id. at 37 (noting that patients who are desperate for money will participate in trials specifically 
for the monetary compensation). 
 217. Id. at 39.   
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people.218  Data aggregators actually sell email lists labeled “sucker lists” of gul-
lible people.219 
As pharmaceutical companies harvest increasingly rich sources of con-
sumer and patient data, they are likely to adjust their product development prior-
ities.220  The profiles generated from online and offline data may reveal relation-
ships between particular conditions and optimal consumer populations—those 
who are wealthier, more likely to adhere to brand-name drugs, more likely to 
influence prescribing practices, or more likely to accept stigmatized diagno-
ses.221  In addition, extensive behavioral data available about people based on 
their activities across the web can enable researchers to identify and recruit sub-
jects who typically do not complain, thus leading to approval of a drug that has 
undocumented side effects.  The development of treatments based on inequitable 
recruitment in virtual clinical trials may thus undermine the social goal of devel-
oping safe and effective treatments for the entire population. 
V. INFORMED CONSENT 
Informed consent is an essential prerequisite to medical research.222  People 
cannot be required to be guinea pigs.  A basic human right exists to refuse to 
participate in research for whatever reason.223  In fact, the first principle of the 
 
 218. Nathan Newman, How Big Data Enables Economic Harm to Consumers, Especially to Low-
Income and Other Vulnerable Sectors of the Population, 18 J. INTERNET L. 11, 14 (2014). 
 219. Id. at 14. 
 220. Jamie Cattell, et al., How Big Data Can Revolutionize Pharmaceutical R&D, MCKINSEY & 
COMPANY (Apr. 2013), http://www.mckinsey.com/industries/pharmaceuticals-and- medical-prod-
ucts/our-insights/how- big-data- can-revolutionize- pharmaceutical-r- and-d. 
 221. Id. (explaining that pharmaceutical companies can use data mining to identify new potential drugs 
and focus R&D resources on drugs that are likely to be successful).  Researchers might themselves choose 
only the wealthiest subjects by using data from their choice of websites (such as high end shopping sites) 
or their use of expensive digital devices. This allows the recruitment of subjects who will be able to afford 
expensive treatments. The pricing of the resulting treatment might prevent others from having access to 
the benefits of the research. 
 222. NUERNBERG MILITARY TRIBUNALS VOL. II, supra note 29, at 181–182. 
 223. See generally World Medical Association, Declaration of Helsinki–Ethical Principles for Medi-
cal Research Involving Human Subjects, 5, http://www.wma.net/en/30publications/10policies/b3/in-
dex.html.pdf?print-media-type&footer-right=[page]/[toPage] (last amended Oct. 2013) (explaining that 
all subjects must be notified of their right to refuse to participate in a study).  
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Nuremberg Code, the international standard for medical research, is that partici-
pation must be informed and voluntary.224  Similar provisions exist in U.S. fed-
eral research regulations, which apply to all federally-funded research225 and to 
research that will be used in efforts to obtain Food and Drug Administration ap-
proval for a drug or other product.226  The federal regulations, influenced by the 
Nuremberg Code, have extensive requirements regarding what must be disclosed 
to potential research subjects and what must be done to ensure that a person is 
not coerced into participating in research.227  The regulations also require that 
informed consent forms include a “statement that participation is voluntary.”228  
The subject’s right to be informed about the risks and benefits of the proposed 
research before they are enrolled in a research study and the right to refuse to 
participate in research is also part of medical ethics codes229 and common law 
legal obligations.230  For certain vulnerable groups—such as children—addi-
tional protections are in place under the federal research regulations.231  Because 
 
 224. See NUERNBERG MILITARY TRIBUNALS VOL. II, supra note 29, at 181–82. The first tenet of the 
Nuremberg Code is: “1. The voluntary consent of the human subject is absolutely essential. This means 
that the person involved should have legal capacity to give consent; should be so situated as to be able to 
exercise free power of choice, without the intervention of any element of force, fraud, deceit, duress, over-
reaching, or other ulterior form of constraint or coercion; and should have sufficient knowledge and com-
prehension of the elements of the subject matter involved, as to enable him to make an understanding and 
enlightened decision. This latter element requires that, before the acceptance of an affirmative decision by 
the experimental subject, there should be made known to him the nature, duration, and purpose of the 
experiment; the method and means by which it is to be conducted; all inconveniences and hazards reason-
ably to be expected; and the effects upon his health or person, which may possibly come from his partic-
ipation in the experiment.” Id.  
 225. See 45 C.F.R. § 46.122 (2009) (“Federal funds administered by a department or agency may not 
be expended for research involving human subjects unless the requirements of this policy have been sat-
isfied.”); see also 45 C.F.R. § 46.116 (2009) (listing the general requirements for informed consent). 
 226. See 21 C.F.R. § 50.25 (2015) (explaining that informed consent includes a statement noting par-
ticipation is voluntary); see also 21 C.F.R. § 50.1 (2015) (“Compliance with these parts is intended to 
protect the rights and safety of subjects involved.”).  
 227. See 21 C.F.R. § 50.20 (2015) (noting that research shall not be undertaken without informed 
consent and the representative must have a chance to consider whether to participate or not); see also 21 
C.F.R. § 50 (2015) (instructing people to lie because they have gotten the evidence paper as well as as-
signed her extra); 21 C.F.R. § 25 (2015) (explaining that informed consent includes a statement noting 
participation is voluntary); 45 C.F.R. § 46.111(a)(4) (2009) (“Informed consent will be sought from each 
prospective subject.”); 46 C.F.R. § 46.116 (2009) (explaining that investigators must receive informed 
consent from the subject).  
 228. See 21 C.F.R. § 50.25(a)(8) (2015) (noting that participants must receive a statement that partic-
ipation is voluntary); see also 45 C.F.R. § 46.116(a)(8) (2009) (explaining that investigators must receive 
informed consent from the subject). 
 229. The AMA Code of Medical Ethics’ Opinion on Clinical Research, 17 AM. MED. ASS’N J. ETHICS 
1136, 1136–37 (Dec. 2015).  
 230. See Moore v. Regents of the Univ. of Cal., 793 P.2d 479, 483 (1990) (explaining that physicians 
who fail to disclose research or commercial motives will create a cause of action for performing a medical 
procedure without the patient’s informed consent).  
 231. See 45 C.F.R. §§ 46.404–46.409 (2015) (specifying categories of research that are not suitable 
for children and the requirements for proper assent by children to participate in a study); see also 21 C.F.R. 
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of concerns that children cannot meet the requirements of voluntary informed 
consent,232 certain risky research on children is prohibited altogether.233  
Consent collected online—often referred to as electronic consent or e-con-
sent—does not adequately guarantee that the consent is informed or voluntary, 
which is problematic both for the individual and for ensuring the validity of the 
research.234  With online consent, the person signing the consent form may not 
be the person he or she claims to be.235  A reporter was able to lie about her age 
in one of the ResearchKit apps in order to qualify for a study.236  The team behind 
the Parkinson’s ResearchKit app deliberately chose to allow the system to give 
a person more than one opportunity to become eligible for the study: “It’s tough, 
you know—it’s certainly possible to have a system where you only get one shot 
with the eligibility criteria in our studies; but we chose not to do that.”237  
Little is done to verify the identity of research subjects.238  One group of 
online medical researchers suggests that it may be prudent to require a photo ID 
to verify the age and identity of potential subjects.239  This might be possible 
using the same scanning technology that banks use for mobile check deposits,240 
as well as the widely available barcode scanning technology for smartphones.241  
However, a teenager pretending to be an adult could easily scan a parent’s ID to 
 
§§ 50.52–50.54 (2016) (specifying what types of research are permissible by the Food and Drug Admin-
istration when children are the subjects in clinical investigations).  
 232. See, e.g., Teresa Hughes & Mary Kay Helling, A Case for Obtaining Informed Consent From 
Young Children, 6 EARLY CHILDHOOD RES. Q. 225, 227 (1991) (“Children’s limited experiences and 
developmental level make it difficult for them to understand long-term goals of research, the concept of 
risk, and the meaning of self-determination.”). 
 233. See 45 C.F.R. §§ 46.404–46.409 (specifying categories of research that are not suitable for chil-
dren and the requirements for proper assent by children to participate in a study); see also 21 C.F.R. §§ 
50.51–50.56.  
 234. See text accompanying infra at notes 235–257.  
 235. See Duhaime-Ross, supra note 212 (one reporter changed her age on ResearchKit to become 
eligible for a research study, illustrating the issue of minors being able to participate in research despite 
being unable to legally consent).  
 236. Id.  
 237. Id. 
 238. See Considerations and Recommendations Concerning Internet Research and Human Subjects 
Research Regulations, with Revisions, THE SEC’Y’S ADVISORY COMM. ON HUMAN RES. PROTS., HEALTH 
& HUMAN SERVS, at 14 (2013) (explaining that “identity verification is a major issue in Internet re-
search.”); see also id. (describing an online study where she was able to return to the previous page and 
change her age in order to become eligible).  
 239. See Duhaime-Ross, supra note 212.  
 240. See Jeffrey Kopchik, Supervisory Insights, FED. DEPOSIT INS. CORP., https://www.fdic.gov/reg-
ulations/examinations/supervisory/insights/sisum09/primer.html (last updated June 29, 2009) (explaining 
“remote deposit capture” technology in which users take a photo of the check, electronically submitting it 
to the bank, quickly adding credit to the user’s bank account).  
 241. See Jesse Emspak, Smartphone App Foils Would-Be Underage Drinkers, MASHABLE, (July 11, 
2013), http://mashable.com/2013/07/11/barzapp-app-underage-drinkers/#CpmP8ISsGkqy (describing a 
new smartphone app, BarZapp, which scans the barcode on the back of an ID and instantly verifies the 
age of a person).  
  
2018] VIRTUAL CLINICAL TRIALS 221 
meet the criteria.  Furthermore, requiring participants to provide additional per-
sonal data increases the risk of identity theft.242  
The online consent process also eliminates the role of an intermediary ca-
pable of evaluating patient capacity and voluntariness, which are requisite for 
informed consent.243  Can a software program adequately detect impairments in 
the functional abilities involved in subject comprehension of information and use 
of information to evaluate the desirability of the balance between the study’s 
risks and potential benefits?  Can software detect extreme influences on the pa-
tient’s indicated preferences, such as overwhelming family pressure to partici-
pate in the study for the possible therapeutic benefit, compensated care, or even 
payments for participation?  
Furthermore, by removing the informed consent process from an in-person 
setting, online research eliminates a crucial aspect of the process, which is the 
dialogue between a potential subject and an investigator.244  Is there sufficient 
dialogue and interaction to make the informed consent process meaningful when 
the subject is simply tapping through e-consent prompts on a tablet screen?245  
Making the informed consent process entirely digital hinders opportunity for 
such dialogue to take place.246  In a virtual clinical trial, without in-person phy-
sician oversight, a participant’s additional conditions or use of drugs may go un-
noticed, and lead to increased risks during the experimental treatment.247  
 
 242. See, e.g., Lorenzo Franceschi-Bicchierai, Uber Left Hundreds of Drivers’ Licenses and Social 
Security Numbers Exposed, MOTHERBOARD (Oct. 13, 2015, 6:52 PM), http://mother-
board.vice.com/read/uber-left-hundreds-of-drivers-licenses-and-social-security-numbers-exposed?111 
(describing a data breach of Uber that exposed hundreds of drivers’ licenses, tax forms, and social security 
numbers); see also Ted Samson, Flaw in Popular Mobile Apps Exposes Users to Identity Theft, 
INFOWORLD (Apr. 9, 2012), http://www.infoworld.com/article/2617115/mobile-security/flaw-in-popu-
lar-mobile-apps-exposes-users-to-identity-theft.html (describing a flaw in popular mobile apps such as 
Facebook, Dropbox, and LinkedIn, which exposed users to identity theft “by saving user authentication 
keys in easily accessible, unencrypted plain text files.”).   
 243. See Umesh Chandra Gupta, Informed Consent in Clinical Research: Revisiting Few Concepts 
and Areas, 4 PERSP. IN CLINICAL RES. 26, 26–27, 29 (2013) (explaining that the three essential elements 
of informed consent are “voluntarism, information disclosure, and decision-making capacity”; researchers 
are responsible for ensuring patients are participating voluntarily, provided with information relevant to 
making an informed decision, and able to understand and appreciate the decision they are making). 
 244. See Duhaime-Ross, supra note 212 (“Despite some improvements to the informed consent pro-
cess, one problem remains: many of these apps haven’t figured out a way to let users ask a question during 
the process, which is what the one-on-one interaction allows.”); see also INST. OF MED. OF THE NAT’L 
ACADS., RESPONSIBLE RESEARCH: A SYSTEMS APPROACH TO PROTECTING RESEARCH PARTICIPANTS 
120–23 (Daniel D. Federman et al. eds., 2003) (recommending that informed consent should consist of an 
“ongoing, interactive dialogue between research staff and research participants”).  
 245. See Christine Coughlin, E-Consent: Can Informed Consent be Just a Click Away?, 50 WAKE 
FOREST L. REV. 381, 394–95 (2015), at 394 (explaining that subjects are far less likely to read consent 
forms “on a screen or a tablet versus a hard copy”). 
 246. Duhaime-Ross, supra note 212; see also supra text accompanying note 243. 
 247. See Coughlin, supra note 245, at 395 (explaining that reducing in-person interactions “increases 
the likelihood that physicians would not recognize shifting patient vulnerabilities.”). 
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To the extent that the companies have made the electronic consent forms 
available, it appears that the forms allow the participants’ information to be used 
beyond the initial study in studies the person has not specifically consented to.248  
This conflicts with the principle that people should be informed about the partic-
ular nature and risk of a study that they are being asked to participate in.  It also 
runs afoul of the clear evidence, from studies249 and cases,250 that research sub-
jects have strong feelings about the types of research they want to participate in.  
People’s consent to one type of research does not imply consent to another type 
of research.251  If information voluntarily provided for one study is used without 
 
 248. See Marianne Kolbasuk McGee, Apple’s ResearchKit: The Privacy Issues, DATA BREACH 
TODAY (Mar. 16, 2015), http://www.databreachtoday.com/apples-researchkit-privacy-issues-a-8018 (ex-
plaining that although Apple’s ResearchKit provides informed consent to consumers prior to participating 
in clinical studies through an app, “[i]t’s not clear how ResearchKit and end users determine which apps 
have access to what data, for what purposes, and for how long.” Furthermore, once an entity has a con-
sumer’s personal information “there is no way to know what they do with it . . . It is also relatively easy 
for a “malicious developer” to create an app and divulge private information.).  See Valerie Gutmann 
Koch, PGTandMe: Social Networking-Based Genetic Testing and the Evolving Research Model, 22, 51 
HEALTH MATRIX 33 (2012) (noting that using a person’s information in “studies that were not identified 
at the time of enrollment challenges current expectations of how research protocols are defined and what 
it means to participate in research.”). The strength of research subjects’ desire to determine what type of 
research is performed on their information or samples is evinced by the fact that research subjects have 
sued research institutions that have used their samples for studies beyond the initial consented-to research. 
See, e.g., Havasupai Tribe of Havasupai Reservation v. Ariz. Bd. of Regents, 204 P.3d 1063 (Ariz. Ct. 
App. 2008). 
 249. See M.L. Goodson & B.G. Vernon, A Study of Public Opinion on the Use of Tissue Samples from 
Living Subjects for Clinical Research, 57 J. CLINICAL PATHOLOGY 135, 136–37 (2004) (asserting that 
many participants seek control over their tissues and will only join types of research that allows that con-
trol); see also Åsa Kettis-Lindblad et al., Perceptions of Potential Donors in the Swedish Public Towards 
Information and Consent Procedures in Relation to Use of Human Tissue Samples in Biobanks: A Popu-
lation-Based Study, 35 SCANDINAVIAN J. PUB. HEALTH 148, 155 (2007) (suggesting that research proce-
dures should be specialized based on the preferences of the participant); Briana Mezuk et al., Participant 
Characteristics That Influence Consent for Genetic Research in a Population-Based Survey: The Balti-
more Epidemiologic Catchment Area Follow-up, 11 COMMUNITY GENETICS 171, 173–76 (2008) (stating 
that their study shows that people are influenced into participating by many variables); Jeanette M. Trauth 
et al., Public Attitudes Regarding Willingness to Participate in Medical Research Studies, 12 J. HEALTH 
& SOC. POL’Y 23, 39–40 (2000) (focusing on what life experiences influence people the most to participate 
in certain research studies); Lori B. Andrews and Julie Burger Chronis, A Pound of Flesh: Patient Legal 
Action for Human Research Protections in the Biotech Age, in PATIENTS AS POLICY ACTORS 83 (2011); 
Lori B. Andrews, Assessing Values to Set Policies for Consent, Storage, and Use of Tissue and Infor-
mation in Biobanks, in NEW CHALLENGES FOR BIOBANKS: ETHICS, LAW AND GOVERNANCE 31 (2009).   
 250. See Washington Univ. v. Catalona, 490 F.3d 667, 673 (8th Cir. 2006) (allowing research partic-
ipants to intervene and attempt to direct the transfer of their biological samples); see also Havasupai Tribe 
v. Ariz. Bd. of Regents, 204 P.3d 1063 (Ariz. Ct. App. 2008) (tribe whose blood was collected for diabetes 
research objected to its use in other studies). 
 251. See Greenberg v. Miami Children’s Hosp. Research Inst. Inc., 208 F.Supp.2d 918, 921–22 (N.D. 
Ill. 2002) (involving participants who sued a research hospital and researcher when their biological sam-
ples were used to file for a patent rather than provide support on an affordable and accessible basis). 
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specific consent for a different study, the nature of the latter study may be objec-
tionable to the participant.252  The participant may have been drawn to the initial 
research because it focused on a disease that affected his or her family and may 
not wish to participate in other research.253  Also, the trust that the subjects have 
in the initial researcher may not carry over to unspecified future researchers.254   
There is reason to suspect that the risks of participation are not adequately 
explained in a digital informed consent form.255  It is unlikely that such forms 
include disclosure of the risks of stigmatization or discrimination associated with 
the aggregation of data about an individual.256  The informed consent form may 
even fail to adequately disclose the risks of the drug being used in the research.257   
Some of the research studies undertaken via virtual clinical trials involve 
drugs which have been approved by the FDA to treat one condition being used 
for another condition.258  Miguel Orri, then Senior Director at Pfizer said that in 
the original REMOTE trial, researchers used “an approved drug, with a well-
established safety profile in a condition where patients don’t die” (emphasis 
 
 252. See Goodson & Vernon, supra note 249, at 136–37 (saying that many participants want some 
type of control over their tissues and want to be consulted when their tissues are used for a different study); 
see also Kettis-Lindblad et al., supra note 249, at 154–55 (suggesting that there should be informed con-
sent every time there is a different study than was originally entered into); see also Marc D. Schwartz et 
al., Consent to the Use of Stored DNA for Genetics Research: A Survey of Attitudes in the Jewish Popu-
lation, 98 AM. J. MED. Genetics 336-341 (2001) (noting that people want researchers to get their informed 
consent each time their tissues are used for different research). 
 253. See Trauth et al., supra note 249, at 31–40 (finding that those with sick family members and 
friends were significantly more willing to participate in medical research trials). 
 254. See Havasupai Tribe v. Ariz. Bd. of Regents, 204 P.3d 1063 (Ariz. Ct. App. 2008) (explaining 
that the Havasupai Tribe agreed to participate in a study focused on diabetes after a researcher developed 
a strong relationship with the tribe, then sued when they found out that their blood samples were used for 
projects that were not related to diabetes). 
 255. See Coughlin, supra note 245, at 382, 393–95. 
 256. See Eric T. Juengst, Human Genetics ‘98: Ethical Issues In Genetics, Group Identity and Human 
Diversity, 63 AM. J. HUM. GENETICS 673, 673, 677 (1998) (explaining that research that finds a genetic 
propensity for alcoholism in a particular group could be misinterpreted and applied to all members of a 
the group in a discriminatory way and arguing that individuals should be informed of this risk); see also 
Schwartz et al., supra note 252, at 336, 341 (surveying Jewish individuals and finding that they were less 
willing to participate in research regarding stereotypical or potentially stigmatizing traits). 
 257. See I. N. Olver et al., The Adequacy of Consent Forms for Informing Patients Entering Oncolog-
ical Clinical Trials, 6 ANNALS OF ONCOLOGY 867, 867–69 (1995) (discussing how many participants 
could not name the severe side-effects of drugs even after reading the consent form). 
 258. See Jean Fain, A Miracle Drug For Binge Eating? Not So Fast, Says Therapist, WBUR (Feb. 10, 
2015), http://www.wbur.org/commonhealth/2015/02/10/a-miracle-drug-for-binge-eating-not-so-fast-
says-therapist (the use of Vyvanse for binge eating disorder would have severe side-effects for the user, 
even though it has been approved for another condition). 
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added).259  Yet, just because a drug has been approved for a particular condition 
does not mean it is 100% safe or that it will be safe for another condition.260  
Virtual clinical trials are used to study new uses of old drugs.261  Pharma-
ceutical companies are rebranding some of their top-selling drugs and marketing 
them for a different condition either because the patent is running out or simply 
because they want to expand the market for the drugs.262  The researcher under-
taking a virtual clinical trial with a previously-approved drug might be tempted 
to say in the informed consent form that the drug is “safe” based on previous 
approval.  But the researcher may be failing to take into consideration the risks 
and benefits of the drug in a different circumstance.263  While the risks of a drug 
 
 259. See Kai Langel, Virtual Clinical Trials –”They’re Here to Stay”, ECLINICALHEALTH BLOG (Mar. 
18, 2013), https://www.clinpal.com/clinpal-blog/virtual-clinical-trials-theyre-here-to-stay/. 
 260. See Fain, supra note 258. The author explains that although the drug Vyvanse has been used to 
treat ADHD there may be numerous drawbacks to the use of the drug for the treatment of binge eating 
disorder. Id. 
 261. See Langel, supra note 259 (explaining that the regulators were likely more willing to approve 
the REMOTE virtual trial because the drug was already FDA approved). 
 262. See Mary Ebeling, Beyond Advertising: The Pharmaceutical Industry’s Hidden Marketing Tac-
tics, PRWATCH (Feb. 21, 2008, 12:00 PM), http://www.prwatch.org/news/2008/02/7026/beyond-adver-
tising-pharmaceutical-industrys-hidden-marketing-tactics (explaining that Eli Lilly rebranded Prozac, 
used to treat depression, as Sarafem, used to treat premenstrual dysphoric  disorder, effectively extending 
the patent on Prozac); see also John Russell, Humira: One Drug. Nine Uses. More on the Way?, CHI. 
TRIB. (Sept. 18, 2015), http://www.chicagotribune.com/business/ct-humira-swiss-army-knife-0920-biz-
20150918-story.html (stating that pharmaceutical companies are trying to repurpose old drugs in order to 
gain money by skipping phase one of clinical trials).  
 263. For example, Sarafem has the same exact chemical composition as Prozac, but Sarafem is in-
tended for the treatment of premenstrual dysphoric disorder instead of depression. See Ebeling, supra note 
262. (describing the severe side-effects of Prozac and why it may not be a good idea to use it for other 
conditions). Another example is a drug called Vyvanse—made by the pharmaceutical company Shire—
which was originally used to treat attention deficit hyperactivity disorder (ADHD) but that is now being 
used to treat binge eating disorder because “there was no other drug treatment available for the disorder.” 
See Katie Thomas, Shire, Maker of Binge-Eating Drug Vyvanse, First Marketed the Disease, N.Y. TIMES 
(Feb. 24, 2015), http://www.nytimes.com/2015/02/25/business/shire-maker-of-binge-eating-drug-
vyvanse-first-marketed-the-disease.html?_r=1 (stating that Vyvanse was approved without a committee 
because there was no other drugs available for binge-eating disorder). The FDA did not request review by 
an advisory committee because the drug’s “safety profile is well known.” Id. According to the Physician’s 
Desk Reference website “anaphylaxis/angioedema requiring hospitalization and emergency treatment oc-
curred with 1st or subsequent doses” of Tolterodine tartrate (the drug used for the REMOTE trial). See 
Tolterodine Tartrate—Drug Summary, PDR.NET, http://www.pdr.net/drug-summary/detrol-la?drugla-
belid=477 (last visited Jan. 22, 2017) (describing the effects and warnings of the drug Detrol.); see also 
Stuart Henochowicz, Anaphylaxis, MEDLINEPLUS (Mar. 20, 2016). Similarly, Sarafem contains a boxed 
warning of an increased risk of suicide as well as extensive warnings including possible allergic reactions, 
bleeding, hyponatremia and the potential to “precipitate mixed/manic episode in patients at risk for bipolar 
disorder.” See Fluoxetine Hydrochloride—Drug Summary, PDR.NET, http://www.pdr.net/drug-sum-
mary/Sarafem-Tablets-fluoxetine-hydrochloride-1946.5777 (last visited Jan. 22, 2017) (summarizing the 
drugs warnings and why it might not be smart to use for different conditions); see also Drug Advertising: 
A Glossary of Terms—Boxed Warning, FDA, http://www.fda.gov/Drugs/ResourcesForYou/Consum-
ers/PrescriptionDrugAdvertising/ucm072025.htm (last updated June 19, 2015) (explaining the function of 
a black box warning for drugs). Also, according to the Physicians’ Desk Reference, as a stimulant, 
Vyvanse has a “high potential for abuse and dependence” and may produce anxiety, anorexia, increased 
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might be tolerable when applied to a particular disease, such as one that is par-
ticularly devastating or that has no other treatment, that does not mean there 
would be an identical risk calculus for another disease.264  
The FDA authorized the REMOTE trial because it had been designed to 
test the feasibility and methodology of conducting clinical trials online,265 and 
the FDA wanted to determine how the informed consent process would work 
when done entirely online.266  Mytrus’ electronic informed consent (“eConsent”) 
system is called Enroll.267  Enroll provides the informed consent form and an 
accompanying video in a digital interactive format through an iPad.268  The pro-
cess includes different interactive features and questionnaires to assess the com-
prehension of the participant.269  According to Mytrus, this system will make the 
clinical trial process more cost effective.270  A report indicates that most of the 
ten biggest pharmaceutical companies are using Mytrus’ Enroll electronic con-
sent system,271 and according to Mytrus’ website, 30 IRBs have approved use of 
its Enroll system.272  Other electronic informed consent forms exist, such as one 
 
heart rate, sudden death and stroke. See Lisdexamfetamine Dimesylate—Drug Summary, PDR.NET, 
http://www.pdr.net/drug-summary/vyvanse?druglabelid=538 (last visited Jan. 22, 2017) (explaining the 
warnings of using Vyvanse and suggesting why it might not be smart to use for other conditions). 
 264. See Guidance for Industry: Expedited Programs for Serious Conditions—Drugs and Biologics, 
U.S. DEPT. HEALTH & HUM. SERV. (May 2014), http://www.fda.gov/downloads/drugs/guidancecompli-
anceregulatoryinformation/guidances/ucm358301.pdf  (stating that the FDA is willing to accept greater 
risks and side effects from treatment for serious diseases and therefore some trials should receive acceler-
ated approval); see also Understanding Unapproved Use of Approved Drugs “Off Label”, U. S. DEPT. 
HEALTH. & HUM. SERV. (May 2017), https://www.fda.gov/forpatients/other/offlabel/default.htm (advis-
ing patients considering off label use of FDA approved drugs to weigh the risks and benefits). 
 265. See Pfizer Conducts First “Virtual” Clinical Trial Allowing Patients to Participate Regardless 
of Geography, PFIZER (June 7, 2011), http://press.pfizer.com/press-release/pfizer-conducts-first-virtual-
clinical-trial-allowing-patients-participate-regardless- (stating that the goal of the virtual trial was to test 
this method compared to an on-site clinical trial). 
 266. See Mike Mitka, Strategies Sought for Reducing Cost, Improving Efficiency of Clinical Research, 
306 JAMA 364, 365 (2011). 
 267. Reinvent Consent with Enroll, MYTRUS, https://www.mytrus.com/en/products-services/enroll 
(last visited Jan. 22, 2017). 
 268. See id. (denoting the Enroll app’s operation through an iPad). 
 269. See id. (discussing the features Enroll uses to enhance a clinical trial participant’s understanding). 
 270. See Kristen Schneider, Mytrus Pioneers to Patient-Friendly Technologies for Clinical Trials Par-
ticipation, SARTA (May 9, 2014), http://sarta.org/blog/mytrus-pioneers-to-patient-friendly-technologies-
for-clinical-trials-participation/ (addressing the increased cost efficiency of the Enroll system). 
 271. Id. 
 272. Reinvent Consent With Enroll, supra note 267. 
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designed by Sage Bionetworks that uses icons and explanations273 and one de-
signed by surgeons at the Medical College of Wisconsin.274 
Enroll allows subjects to flag terms they do not understand and click 
through to obtain more information, and in some cases even call a person.275  The 
system also collects data regarding how long a patient looked at each screen of 
the electronic informed consent form on the iPad and regarding sections where a 
participant had trouble understanding a particular idea or word.276  However, this 
system cannot determine if the subjects’ consent is either informed or volun-
tary.277  The system is not designed to eliminate someone who reads the informed 
consent disclaimer in just a few seconds or who genuinely does not understand 
certain aspects of the study.278  Furthermore, the eConsent model does not ad-
dress the difficulty in ascertaining whether the person signing the eConsent form 
in an entirely online clinical trial is actually the subject participating in the re-
search study.279  
The FDA notes that although use of the electronic informed consent may 
make research easier for sponsors, they “must attend to privacy and confidenti-
 
 273. See John Wilbanks & Erin Holve, EDM Forum’s Collaborative Network, PCOR, and Apple’s 
Research Kit, ACADAMYHEALTH (Apr. 14, 2015), http://www.academyhealth.org/blog/2015-04/edm-fo-
rums-collaborative-network-pcor-and-apples-research-kit (discussing the two tiers of Sage Bionetworks 
system, the first tier being “icon dominant” and the second tier being more text and detail dominant). 
 274. See Matthew J. Frelich et. al., Research Electronic Data Capture (REDCap) Electronic Informed 
Consent Form (eICF) is Compliant and Feasible in a Clinical Research Setting, 2 INT’L J. CLINICAL 
TRIALS 51, 52 (2015) (addressing the creation of an electronic informed consent by Vanderbilt University 
with partners such as the Medical College of Wisconsin). 
 275. See Ann Neuer, Informed Consent Goes Digital, CLINICAL INFORMATICS NEWS (Aug. 29, 2013), 
http://www.clinicalinformaticsnews.com/cln/2013/8/29/informed-consent-goes-digital.html (explaining 
that the subject has the option to select “I understand,” or “I have a question” before getting to the next 
screen; if the subject selects the question option, a site staff then reviews the information with the subject 
and answers any questions). 
 276. Id. 
 277. See NUERNBERG MILITARY TRIBUNALS VOL. II, supra note 29, 181–182 (discussing the high 
standard for consent to be both informed and voluntary and allowing inference that the standard would be 
difficult to meet through Mytrus’s electronic Enroll system). 
 278. See Reinvent Consent With Enroll, supra note 267 (noting Enroll’s capabilities, which do not 
include the ability to screen out participants who read the informed consent too quickly or who are genu-
inely confused about a study). 
 279. See Reinvent Consent With Enroll, supra note 267 (highlighting Enroll’s capabilities, which do 
not address imposters in clinical trials); see also Duhaime-Ross, supra note 212 (discussing the risk of 
imposters and false claims of identity in clinical trials). 
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ality concerns when considering techniques for monitoring informed consent re-
motely.”280  Although the FDA’s main concern seem to be the accuracy and qual-
ity of the data obtained from the trial,281 equally important is the vulnerability of 
access to private health information.  Data breaches involving protected health 
information have increased exponentially.282 As a result of the expected expan-
sion in the use of electronic health records and cloud storage services, data 
breaches of health information are expected to increase.283  
Informed consent is a crucial component of research on human subjects 
because protection of an individual’s autonomy to make decisions for himself or 
herself is not only legally required, but widely recognized as a fundamental prin-
ciple of medical ethics.284  The informed consent methodology used in virtual 
clinical trials does not adequately protect research participants.  
VI. CONFIDENTIALITY AND PRIVACY 
The disclosure of health information is a sensitive matter.  The quality of 
health care is based primarily on information that physicians get directly from 
their patients.285  If patients withhold information from their physicians, it may 
lead to ineffective care or even to potentially unnecessary procedures leading to 
 
 280. See U.S. Dep’t Health & Hum. Serv. et al., Guidance of Industry: Oversight for Clinical Investi-
gations—A Risk-Based Approach to Monitoring, FDA GUIDANCE DOCUMENTS (Aug. 2013), at 9, 
http://www.fda.gov/downloads/Drugs/. . ./Guidances/UCM269919.pdf. 
 281. See id. at 1, 11 (explaining that the “nonbinding recommendations” provided by the FDA center 
around ensuring that a site’s records are complete, that the information regarding subjects be accurate, and 
that there is a low frequency of protocol violations).   
 282. See Vincent Liu et al., Data Breaches of Protected Health Information in the United States, 313 
JAMA 1471, 1472 (2014). A study in the April 14, 2015 JAMA issue reported that “between 2010 and 
2013, breaches of protected health information reported by HIPAA-covered entities increased and in-
volved approximately 29 million records, with most data breaches resulting from overt criminal activity.” 
The study focused on a U.S. Department of Health and Human Services database which listed “data 
breaches of unencrypted protected health information.” The authors noted that most of such breaches 
(67%) occurred through the use of electronics—such as computers. They further noted that due to the fact 
that they used data pertaining to reported breaches only “[their] study likely underestimated the true num-
ber of health care data breaches occurring each year.” 
 283. See id. (predicting that data breaches are likely to increase because of increased use of “cloud 
based services provided by vendors supporting predictive analytics, personal health records, health-related 
sensors, and gene sequencing technology”). 
 284. 21 C.F.R. § 50.20 (2016); 45 C.F.R. § 46.116; THE NAT’L COMM’N FOR THE PROT. OF HUM. 
SUBJECTS OF BIOMED. AND BEHAV. RESEARCH, supra note 176, at 10. 
 285. See, e.g., Kevin McCarthy, Study: 50 Percent of Patients Withhold Information from their Doc-
tor, NUEMD (Sept. 21, 2016), http://www.nuemd.com/news/2014/12/19/study-50-percent-patients-with-
hold-information-their-doctor (“Patients who withhold information about their medication use are increas-
ing their chances of experiencing an adverse drug event, and individuals who lie about their diet or activity 
level may be withholding valuable diagnostic clues.”). 
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higher health care costs.286  Therefore, it is vital to ensure that an individual’s 
health information remains private so that patients are willing to answer sensitive 
questions honestly.287  Furthermore, unwanted disclosures of private health in-
formation may lead to discrimination, stigmatization, embarrassment, denial of 
services and benefits, as well as other serious adverse consequences.288  
Various federal laws have been adopted to protect health information spe-
cifically, such as the privacy regulations289 adopted under the Health Insurance 
Portability and Accountability Act290 and the federal research regulations, which 
state that Institutional Review Boards must determine whether a research plan 
contains adequate safeguards to protect the subjects’ privacy and confidentiality 
prior to approving a study.291  Some states have also enacted measures to protect 
people’s health information.292 
However, many of the federal and state legal protections fail to protect med-
ical information online.  For example, the privacy regulations293 adopted under 
HIPAA294 only apply to specifically-defined “covered entities,” which include 
health care providers and plans, but not internet sites where researchers conduct 
online medical research.  State laws are also limited in the type of health infor-
mation that they protect295; for example, Rhode Island’s law related to the pri-
vacy and confidentiality of medical information prohibits “any person” from dis-
closing a patient’s “confidential health care information” without the patient’s 
 
 286. See, e.g., Sally E. Thorne et al., Is There a Cost to Poor Communication in Cancer Care?: A 
Critical Review of the Literature, 14 PSYCHO-ONCOLOGY 875, 879–80 (2005) (reviewing empirical liter-
ature of communication between cancer patients and their doctors and finding that poor communication 
leads to higher healthcare costs). 
 287. See Katherine M. Woods & Regis McNamara, Confidentiality: Its Effect on Interviewee Behav-
ior, 11 PROF. PSYCHOL. 714, 719 (1980) (describing a study in which interviewees who were told their 
answers might not be confidential disclosed less information). 
 288. INST. OF MED, BEYOND THE HIPAA PRIVACY RULE: ENHANCING PRIVACY, IMPROVING HEALTH 
THROUGH RESEARCH 77 (Sharyl J. Nass et al. eds., 2009). 
 289. The HIPAA Privacy Rule, 45 C.F.R. § 160 (2016); 45 C.F.R. § 164.102–106 (2016); 45 C.F.R. 
§ 164.500–534 (2016). 
 290. The Health Insurance Portability and Accountability Act of 1996, Pub. L. No. 104-191, 100 Stat. 
1936 (codified as amended in scattered sections of 26, 42 U.S.C.). 
 291. See 45 C.F.R. § 46.111(a)(7) (2015) (“In order to approve research covered by this policy the 
IRB shall determine that [among other things] . . . [w]hen appropriate, there are adequate provisions to 
protect the privacy of subjects and to maintain the confidentiality of data.”). 
 292. See, e.g., R.I. GEN. LAWS § 5-37.3-4 (2016) (requiring written consent of the patient prior to the 
release or transfer of confidential health care information); see also CAL. CIV. CODE § 56.06 (a), (b) (West 
2016) (requiring that businesses that offer software or hardware for maintaining medical information be 
held to the same standards of confidentiality as health care providers). 
 293. See 45 C.F.R. § 160.103 (2015) (defining covered entities as a health plan, a health clearing 
house, or a health care provider who transmits health information electronically). 
 294. The Health Insurance Portability and Accountability Act of 1996, Pub. L. No. 104-191, 100 Stat. 
1936 (codified as amended in scattered sections of 26, 42 U.S.C.). 
 295. 45 C.F.R. § 160.103 (2015). 
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consent.296 This law, however, only protects confidential health care information 
related to “health care history, diagnosis, condition treatment or evaluation ob-
tained from a health care provider who has treated the patient.”297  Such narrow 
protections ignore the high risks associated with the collection of exactly the 
same types of information by different entities merely because those entities are 
not involved with treating the patient. 
Some states have begun to express concern about health care information 
disclosure online.  California and Delaware, for example, require that websites 
that collect personally identifiable information post a privacy policy about the 
type of information they collect. 298  An additional California law requires that 
“any business that offers software or hardware to consumers” with the purpose 
of allowing consumers to “maintain medical information” or for “the diagnosis, 
treatment, or management of a medical condition” be considered as “a provider 
of healthcare” for purposes of requiring such entity to maintain “the same stand-
ards of confidentiality required of a provider of health care with respect to med-
ical information disclosed to the business.” 299  This means that disclosures of 
health information by such medical apps or websites for the purpose of recruit-
ment would be considered actionable as a breach of confidentiality.  In addition, 
unauthorized disclosure of health information to marketers or third parties that 
was collected during the study through the app designed to monitor health would 
be actionable.300  
Researchers who conduct virtual clinical trials may inadvertently violate 
their subjects’ privacy.  This can happen in a variety of ways—from accessing 
and combining private data to determine who should be recruited into a study,301 
to passively collecting data without consent (such as measuring a person’s speech 
pattern through an app’s use of a phone’s microphone302 or the person’s gait 
 
 296. R.I. GEN. LAWS § 5-37.3-4 (a)(1)–(2) (2016). 
 297. R.I. GEN. LAWS § 5-37.3-3 (3)(ii) (2016). 
 298. CAL. BUS & PROF. CODE § 22575 (a), (b)(1) (West 2013); DEL. CODE ANN. 6, § 1205C (a), (b)(1) 
(2016). 
 299. CAL. CIV. CODE § 56.06(a)–(c) (West 2009). 
 300. See CAL. CIV. CODE §56.36 (b)(1)–(2) (West 2007) (providing penalties for the violation of the 
confidentiality provision in the form of a private cause of action); see also, CAL. CIV. CODE § 56.36 (a), 
(c) (West 2007) (providing for further penalties in the form of criminal charges and administrative fines). 
 301. See, e.g., Walker, supra note 104 (highlighting how an individual may have  been targeted for an 
arthritis clinical trial based off of innocuous web-browsing and/or credit card spending). 
 302. See, e.g., Zoe Kleinman, Is Your Smartphone Listening to You?, BBC (Mar. 2, 2016), 
http://www.bbc.com/news/technology-35639549 (highlighting how an android-platform based mobile-
phone application can be easily created to listen in on conversations in the presence of the device that the 
application is installed in). 
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when a phone is in the person’s pocket),303 to storing research data with inade-
quate cyberprotection,304 to aggregating data in a way that puts subjects at risk 
of disclosure of private facts leading to stigmatization and discrimination.305 
Virtual clinical trial researchers have created a market for privacy viola-
tions, incentivizing data aggregators’ collection of data in much the same way 
they originally created the market that encouraged physicians to enroll their own 
patients in clinical trials.  Commentators criticized this earlier system because it 
incentivized physicians to behave in unscrupulous ways in order to get large 
sums of money from pharmaceutical companies in exchange for enrolling their 
patients.306  Now, researchers are encouraging data aggregators to invade peo-
ple’s privacy through the surreptitious collection of data, thereby creating this 
new market.307  Because the HIPAA Privacy Rule does not cover online medical 
data that is not in the control of health care institutions or health care providers, 
entities that sell consumers’ private data to researchers can violate people’s pri-
vacy in their attempt to identify research subjects.308  Data can be legally col-
lected about people’s private web searches, social media posts and even their 
private email messages to friends, and can be used to recruit subjects based on 
inferred characteristics.309  Theses technically legal practices that researchers use 
 
 303. See, e.g., Apple Announces New ResearchKit Studies for Autism, Epilepsy & Melanoma, APPLE 
(Oct. 15, 2015), http://www.apple.com/pr/library/2015/10/15Apple-Announces-New-ResearchKit-Stud-
ies-for-Autism-Epilepsy-Melanoma.html; see also ResearchKit and CareKit; Empowering Medical Re-
searchers, Doctors, and Now You, APPLE, http://www.apple.com/researchkit/ (last visited Jan. 22, 2017) 
(discussing how the “mPower” app is helping researchers understand Parkinson’s disease by using iPhone 
features to measure, along-side of other features, gait). 
 304. See, e.g., Improper Disclosure of Research Participants’ Protected Health Information Results 
in $3.9 Million HIPAA Settlement, U.S DEPT. HEALTH & HUM. SERV. (Mar. 17, 2016), 
http://www.hhs.gov/about/news/2016/03/17/improper-disclosure-research-participants-protected-health-
information-results-in-hipaa-settlement.html (detailing how the Feinstein Institute for Medical Research 
was fined for, among other things, storing research data without appropriate cyber-protection which led 
to a breach of that data). 
 305. See Leslie Wolf et al., Certificates of Confidentiality: Protecting Human Subject Research Data 
in Law and Practice, 14 MINN. J.L. SCI. & TECH. 11, 16–17 (2013) (demonstrating how research data 
collected may be exposed through litigation, exposing participants to stigmatization). 
 306. See generally Trudo Lemmens & Paul B. Miller, The Human Subjects Trade: Ethical and Legal 
Issues Surrounding Recruitment Incentives, 31 J.L. MED. & ETHICS 398, 401 (2003) (discussing how “fi-
nancial pressures may bring physicians to stretch the inclusion and exclusion criteria [of a clinical trial 
testing a new medication] to enroll as many patients as they can, thereby compromising the trial’s valid-
ity”). 
 307. See generally Sorrell v. IMS Health Inc., 564 U.S. 552 (2011) (health data miners prevailed in a 
First Amendment challenge to a Vermont statute that protected the privacy of information about doctors’ 
prescribing patterns); also see generally Erika Check Hayden, Mobile-Phone Health Apps Deliver Data 
Bounty, 531 NATURE 422 (2016), http://www.nature.com/news/mobile-phone-health-apps-deliver-data-
bounty-1.19622 (noting that researchers are realizing the value of collecting health data through apps and 
the scope of such programs is expanding). 
 308. See generally Nicholas P. Terry, Big Data Proxies and Health Privacy Exceptionalism, 24 
HEALTH MATRIX: J.L.-MED. 65, 84–87 (2015) (describing “medically infected data,” data that although 
is not strictly medical, can be collected to infer medical status yet fall outside the scope of HIPPA’s reach). 
 309. Walker, supra note 104. 
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to collect people’s data are nonetheless particularly intrusive and violate people’s 
privacy.310   
Targeted advertisements to recruit clinical trial participants also raise pri-
vacy concerns.311  For example, if a person Googles a disease, a clinical trial ad 
can appear related to that disease312 on another Google service.  Imagine watch-
ing a YouTube video with your child when an advertisement appears asking you 
to participate in a clinical trial about cancer or sexually-transmitted diseases be-
cause you have searched for information about the condition online. 
Once researchers identify a potential subject, new privacy risks arise. Vir-
tual clinical trials collect data online, often through medical apps.313  However, 
computers and cell phones are riddled with surreptitious tracking mechanisms 
such as cookies.314  Medical and clinical trial apps are sometimes designed to 
send private health information to data aggregators.315  A study conducted at IIT 
Chicago-Kent College of Law about diabetes apps found that over 80% of the 
apps sent user health information to third-party data aggregators.316 
The virtual clinical trial model also presents unique privacy issues because 
of the nature of digital information and storage.  Because the information for 
such trials is stored and transmitted exclusively online through computers or mo-
bile devices, any party besides the subject of an online clinical trial can poten-
tially gain access to the information by using the device without the subject’s 
authorization.317  Since trial information—including informed consent forms and 
 
 310. Terry, supra note 308 at 84–85 (providing examples of where data are collected including “web-
browsing trails, exhaust data from online transactions, web scrapers, social media interactions, mobile 
phone usage, smartphone sensors, mobile health apps, and both medical and non-medical networked de-
vices”). 
 311. See, e.g., Brenda L. Curtis, Social Networking and Online Recruiting for HIV Research: Ethical 
Challenges, 9 J. EMPIRICAL RES. HUM. RES. ETHICS 58, 59–60 (2014), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316828/pdf/nihms576496.pdf (describing privacy is-
sues associated with targeted online recruiting for HIV research). 
 312. See Privacy Policy, GOOGLE, https://www.google.com/policies/privacy/#nosharing (last visited 
Jan. 22, 2017). 
 313. Maged N. Kamel Boulos et al., Mobile Medical and Health Apps: State of the Art, Concerns, 
Regulatory Control and Certification, 5 ONLINE J. PUB. HEALTH INFORMATICS 1, 4 (2014) (describing 
trials that use mobile apps to collect health information such as body weight, calorie loss and disease-
symptoms). 
 314. See Jonathan R. Mayer & John C. Mitchell, Third Party Web Tracking: Policy and Technology, 
CTR. FOR INTERNET & SOC’Y (2012), https://jonathanmayer.org/papers_data/trackingsurvey12.pdf (dis-
cussing methods of tracking mechanisms such as “cookies”).  
 315. See Sarah R. Blenner et al., supra note 113 (finding that a majority of diabetes apps surveyed use 
tracking cookies to collect user information, and many shared their information with third party data ag-
gregators). 
 316. Id. 
 317. Cf. Kesa Bond et al., Electronic Health Records: Privacy, Confidentiality, and Security, 14 
VIRTUAL MENTOR 712, 714 (2012), http://journalofethics.ama-assn.org/2012/09/stas1-1209.html (noting 
that physicians with unencrypted mobile devices leave digitally transmitted information vulnerable to in-
terception). 
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subjects’ health information—are stored online for clinical trials such as Pfizer’s 
REMOTE, there is the additional risk that a data breach can expose people’s 
sensitive medical data.318 
Some commentators argue that collecting information from websites and 
social media does not constitute an invasion of privacy because such sources are 
generally considered public places.319  However, privacy scholars have argued 
in various contexts that privacy extends to otherwise public places when people 
have a reasonable expectation of privacy about the acts happening in the public 
setting.320  Should it be considered a violation of privacy to use a sound amplifier 
to listen to two people’s conversation in a café?  How about recording such a 
conversation without their consent?  The fact that the internet may be a “public 
place” for some does not mean that traditionally private information put on the 
internet should lose its private nature, especially if it is private health infor-
mation, which has historically been considered amongst the most private infor-
mation about a person. 
In addition, much of the data collected by data aggregators comes from 
online sources that the users themselves view as private—email, password-pro-
tected websites and so forth.321  When people realize that data aggregators are 
collecting extensive information about them, many want legal change.  A 2016 
Pew Research Center study asked participants whether they would join a free 
social media website to communicate with old acquaintances about a class reun-
ion if the website collected information about them to show them targeted adver-
tisements.322  Most of the participants said they would not find that scenario ac-
ceptable.323  Similarly, a Gallup poll found that 67 percent of adult Americans 
opposed being targeted by behavioral advertising and believe that advertisers 
 
 318. See, e.g., James Paul et al., The Internet and Clinical Trials: Background, Online Resources, 
Examples and Issues, J. MED. INTERNET RES. (2005), http://www.ncbi.nlm.nih.gov/pmc/arti-
cles/PMC1550630/?report=printable (asserting that security is a “central issue” when housing trial infor-
mation online, as well as describing ways in which that security can be breached); see also Orri et al., 
supra note 28 at 193–97 (noting that, in a virtual clinical trial, all the study data collected was transferred 
to an electronic database). 
 319. See Solberg, supra note 114 (explaining that courts have found no reasonable expectation of 
privacy in posts on a social media site). 
 320. See, e.g., Carlos A. Ball, Privacy, Property, and Public Sex, 18 COLUM. J. GENDER & L. 1, 33 
(2008) (arguing that the 4th Amendment protections of individuals beyond private residences allows for 
a sexual act occurring in public to take on a private dimension by the nature of the act itself). 
 321. Cf. Blenner et al., supra note 113, at 1051 (finding that a large percentage of diabetes apps, with 
a presumption of privacy, were sold to third party data aggregators). 
 322. See Lee Rainie & Maeve Duggan, Privacy and Information Sharing, PEW RES. CENT., at 31–32 
(Jan. 14, 2016), http://www.pewinternet.org/2016/01/14/privacy-and-information-sharing/ (finding that, 
while many Americans are willing to disclose information for a tangible benefit, they are cautious about 
doing so and are often unsatisfied when they know what a company will do with it). 
 323. Id. at 32. 
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should not be allowed to match advertisements to their particular interests ac-
cording to the websites they have visited.324  The same poll found that 61 percent 
of Americans believe that the use of targeted advertisements is not justified even 
if reduces costs because free access to websites is not worth the invasion of pri-
vacy involved.325  A 2012 Pew poll found that 73 percent of Americans inter-
viewed said they would not be okay with a search engine keeping track of their 
online searches and subsequently using this information to personalize search 
results in the future because it is an invasion of privacy, and 68 percent of par-
ticipants in the same poll said “they are not okay with targeted advertisements 
because they do not like having their online behavior tracked and analyzed.”326 
A breach of privacy in the virtual clinical trial context can exacerbate psy-
chological harms evidenced in other online contexts.327  A teenager who searches 
for a size 14 prom dress or looks up a diet online may be emotionally devastated 
if the subsequent sites that she visits advertise weight loss trials for overweight 
teenagers.  The target of an online advertisement might also face a physical risk, 
if she is lured into an inappropriate clinical trial and subsequently takes medica-
tion when she does not have the target condition.  She may also face a risk if she 
avoids medical care due to the quick fix the “novel” therapy offered through 
participation in a research trial.  Or she may lose the chance to benefit from an 
online support group if she withdraws due to privacy concerns after her name 
has “leaked” to recruiters.  
Surreptitious data collection from social networks for medical research may 
also interfere with patients’ use of the web to gain information or learn from 
other patients.328  A triumph of social networks has been the way people isolated 
 
 324. See Lymari Morales, U.S. Internet Users Ready to Limit Online Tracking for Ads, GALLUP (Dec. 
21, 2010), http://www.gallup.com/poll/145337/Internet-Users-Ready-Limit-Online-Tracking-Ads.aspx. 
 325. Id. 
 326. See Kristin Purcell et al., Search Engine Use 2012, PEW INTERNET & AM. LIFE PROJECT, 18–23 
(Mar. 9, 2012), http://www.pewinternet.org/files/old-media/Files/Re-
ports/2012/PIP_Search_Engine_Use_2012.pdf (finding that a majority of Americans surveyed do not like 
having their online behavior tracked and analyzed). 
 327. Tom Garrubba, 5 Ways Health Data Breaches Are Far Worse Than Financial Ones, 
HEALTHCAREIT NEWS (Nov. 10, 2014), http://www.healthcareitnews.com/news/5-ways-health-data-
breaches-are-far-worse-financial-ones (noting that data breaches may have deadly consequences in the 
health care context); see Charles Ornstein, Small Violations of Medical Privacy Can Hurt Patients and 
Erode Trust, NPR (Dec. 10, 2015), http://www.npr.org/sections/health-
shots/2015/12/10/459091273/small-violations-of-medical-privacy-can-hurt-patients-and-corrode-trust 
(providing an analogous example of the emotional and psychological harm that can result from a breach 
of medical privacy); see also INSTITUTE OF MEDICINE ET AL., BEYOND THE HIPAA PRIVACY RULE 89 
(Nass et al.eds. 2009) (explaining that a breach of private health information can result in a financial harm 
because it may lead to discrimination in health insurance and employment). 
 328. See Maged N. Kamel Boulos & Steve Wheelart, The Emerging Web 2.0 Social Software: An 
Enabling Suite of Sociable Technologies and Health Care Education, 24 HEALTH INFO. & LIBR. J. 2, 13 
(2007) (noting that some users are wary about posting their personal information online because of data 
mining). 
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by distance—or medical conditions—can share intimate information.329  Patients 
who live in remote areas or suffer from rare diseases can come together in a 
seemingly private space to augment their medical care through hearing from oth-
ers with similar symptoms or concerns.330  Social networks and online forums 
are powerful tools to help people kick smoking habits,331 cope with chronic dis-
eases,332 overcome depression,333 monitor their health, and express their frustra-
tion about their condition.334  However, the intrusion of third parties (whether 
advertisers or medical researchers) without the patients’ consent can cause them 
to flee social networks, denying them these potential benefits.335 
A targeted subject also might suffer financial harm if her health information 
is leaked by third parties.  Because of cookies and tracking programs on comput-
ers and cell phones, user information about health concerns and symptoms can 
readily be transmitted to insurance and credit card companies, without the re-
search subject’s knowledge or consent.336  
 
 329. See, e.g., Jae Eun Chung, Social Networking in Online Support Groups for Health: How Online 
Social Networking Benefits Patients, 19 J. HEALTH COMM.: INT’L PERSP. 639, 651–53 (2014) (explaining 
that online support groups provide access to emotional and informational benefits that might otherwise be 
unavailable due to geographic limitations or the rarity of a particular disease). 
 330. Id. 
 331. See Neill Bruce Baskerville et al., Effect of a Digital Social Media Campaign on Young Adult 
Smoking Cessation, 18 NICOTINE & TOBACCO RES. 351, 355–57 (2015) (reporting that young adults had 
greater cessation rates when using social media). 
 332. H. Alan Scott, How Instagram Helps Young People Cope with Cancer, VICE (Mar. 4, 2016), 
http://www.vice.com/read/how-instagram-helps-young-people-cope-with-cancer. 
 333. See Tim Anstiss, How Social Media Is Supporting People with Depression, GUARDIAN (Apr. 26, 
2012), http://www.theguardian.com/social-care-network/2012/apr/26/social-media-depression-support 
(describing how social media provides an empathetic community to assist those suffering with depres-
sion). 
 334. See Felicity Morse, How Social Media Helped me Deal with My Mental Illness, BBC NEWSBEAT 
(Feb. 18, 2016), http://www.bbc.co.uk/newsbeat/article/35607567/how-social-media-helped-me-deal-
with-my-mental-illness (explaining how Yik Yak has provided a platform for patients to express their 
frustrations anonymously).  
 335. See Purcell et al., supra note 326, at 23 (explaining that the majority of people strongly disfavor 
having their online behavior analyzed); see also Bernard Lo & Lindsay Parham, The Impact of Web 2.0 
on the Doctor-Patient Relationship, 38 J.L. MED. & ETHICS 17, at 21 (2010) (explaining how companies 
that sell health products extract information from websites that do not have to abide by HIPPA Health 
Privacy Rule). In addition to the benefits aforementioned in this article, other benefits that authors Lo and 
Parham mention include better access to health information, better access to health care services, enhance-
ment of patient decision-making, psychosocial benefits, and improved doctor-patient relationships. Id. at 
19–20.  There are also risks, such as that of receiving information that is inaccurate and the psychological 
and social risks of learning of a diagnosis over the Internet instead of from a health care professional. Id. 
at 20–21.   
 336. See Michael McFarland, Ethical Implications of Data Aggregation, SANTA CLARA U.: 
MARKKULA CTR. FOR APPLIED ETHICS (June 1, 2012), https://www.scu.edu/ethics/focus-areas/internet-
ethics/resources/ethical-implications-of-data-aggregation/ (warning that aggregated data can be trans-
ferred to a wide variety of marketers and may cause some people to be denied health insurance). 
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VII. VIRTUAL CLINICAL TRIALS AND THE INTEGRITY OF THE RESEARCH 
PROCESS AND ENTERPRISE 
Virtual clinical trials may be beneficial for people who live in rural areas or 
people who have a debilitating condition that inhibits them from traveling to re-
search facilities.337  They may also be beneficial to patients who feel they spend 
enough time in medical settings and do not want to make additional trips to a 
hospital or doctor’s office or who have conditions that cause them to feel embar-
rassed in public.338  However, online medical studies do not provide the most 
robust research results.339  It may be difficult to verify the accuracy and authen-
ticity of the data.340  It may be difficult to verify that, for example, the person 
entering the data is in fact the person participating in the trial, or that the person 
is entering accurate and complete information.  Monetary incentives increase the 
possibility that people who do not suffer from the condition being studied will 
attempt to participate in the trial.  
Virtual clinical trials open the door for people to game the system.  For 
example, if an unqualified individual is rejected from a clinical trial initially 
based on the answers he or she provides in a questionnaire, it is possible for that 
person to create a new email address and therefore create another opportunity to 
be selected.  For a clinical trial that utilizes questionnaires to verify a partici-
pant’s identity, the participant would need to know enough information about 
another person in order to be able to answer the questions. This would be fairly 
simple for anyone with access to a public record database, the individual’s Face-
book page, or if the person is a close friend or a family member (such as a teenage 
child) with access to the intended participant’s information.  
For a trial that requires medical records such as X-rays or that requires a 
preliminary blood test—such as the REMOTE trial—it would be more difficult 
to create a second opportunity to be selected, especially if the lab required the 
participant to show identification before conducting the blood test.  This extra 
safeguard, however, would not work for virtual clinical trials developed for the 
treatment of conditions which are difficult to measure physiologically, such as 
depression and sleep apnea.  In such trials, where no medical documentation of 
 
 337. See Sujay Jadhav, Virtual Clinical Trials: The Future of Patient Engagement?, APPLIED 
CLINICAL TRIAL, at 1 (July 12, 2016), http://www.appliedclinicaltrialsonline.com/virtual-clinical-trials-
future-patient-engagement (explaining the benefits of virtual clinical trials for patients with mobility is-
sues). 
 338. See id. at 1 (identifying the ability of the patient to participate in the clinical trial from home as a 
key advantage associated with virtual clinical trials); see also Richard G. Heimber, Cognitive-behavioral 
Therapy for Social Anxiety: Current Status and Future Direction, 51 BIOLOGICAL PSYCHIATRY 101, 102 
(2002) (explaining how patients with social anxiety disorder may feel humiliated or embarrassed in pub-
lic).   
 339. See text infra accompanying note 341.  
 340. See Allison, supra note 9, at 898 (regarding self-reporting in the context of online medical re-
search generally).  
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the illness is required, it would be easy to create a false profile matching the 
description of the condition—a person may simply search online for the symp-
toms associated with the condition.  
When a research subject is not only recruited online, but also participates 
in the study without the involvement of a traditional research facility, there is an 
increased likelihood of physical harm and inaccurate conclusions about the ex-
perimental treatment. People who do not actually suffer from the conditions at 
issue—or who are minors participating without their parents’ knowledge or con-
sent—and are lured by monetary payment or a free smartphone, may be tempted 
to take an inappropriate drug which might be harmful to them.  If a serious side 
effect or problem occurs, the person may report to their primary care physician 
or local emergency room, instead of the trial investigators who might then be 
unable to evaluate the potential dangers of the drug.  On the other hand, a re-
search subject may simply flush the drugs down the toilet and complete the 
online form reporting no side effects, when serious side effects actually exist.  If 
pharmaceutical companies begin marketing treatments based on the results of 
clinical trials completed entirely remotely, dangers arise not only to the research 
subjects, but also to patients taking the drug after it receives approval as being 
“safe and effective” based on misrepresentations by deceptive participants.341  
Online medical research conducted with social network information may 
also lead to flawed conclusions and can serve as the basis for protocols or thera-
peutics that are ineffective or unduly harm patients because the assumptions 
made about an individual based on her or his social media profile may be 
wrong.342  A person may lie about his or her age or weight on a social network 
profile or use a decade-old photo; a person may post a status update minimizing 
or exaggerating a health problem.  If, for example, a biotechnology company was 
doing research about the impact of alcohol use on people with diabetes, it might 
choose to collect data on people who have searched the term “diabetes” on 
Google or maybe “liked” the American Diabetes Association page on Facebook.  
The biotechnology company might gauge this person’s use of alcohol based on 
whether—and how many times—she or he checked in at a bar on Facebook, or 
had a photo of himself online with a red cup in his hand (a common depiction 
which police routinely use to show that someone under the age of 21 is drinking 
illegally).343  However, such assumptions about a person could be completely 
 
 341. See Ashwaria Gupta, Fraud and Misconduct in Clinical Research: A Concern, 4 PERSP. IN 
CLINICAL RES. 144, 146 (2013) (explaining how fraud can cause harmful medical products to be intro-
duced).  
 342. See Naone, supra note 157 (describing a study that found that social networking data is not a 
reliable source of data). 
 343. See Rupa S. Valdez et al., Beyond Traditional Advertisements: Leveraging Facebook’s Social 
Structures for Research Recruitment, 16 J. MED INTERNET RES. 10 E243 (2014), https://www.jmir.org/ar-
ticle/viewFile/jmir_v16i10e243/2 (explaining that researchers target individuals based on the information 
posted and provided on their social media page); see also KJ Lang, Facebook Turns into Big Brother, 
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wrong: this person may have been going to a bar with friends and abstained from 
drinking alcohol or could have been drinking a non-alcoholic beverage from the 
damning red cup. Or the person who “liked” the American Diabetes Association 
may be expressing solidarity for a friend and might not suffer from diabetes at 
all.  
With the financial incentives for participation and the reliance on self-re-
porting about the effects of the drug or device, there is the probability that par-
ticipants will declare the intervention as beneficial without even taking the drug 
or using the device.344  This may lead to FDA approval of dangerous interven-
tions.345 
Moreover, through the use of data aggregators that collect and sell thou-
sands of pieces of information about people, researchers may be able to identify 
and use a particular research pool—such as healthier people with a particular 
medical condition—that makes their research results look better than if the re-
search had been undertaken on a more diverse or random sample of individu-
als.346  This may lead to the marketing of treatments that pose more risks to the 
end users than the researchers admit. 
VIII. ISSUES REGARDING IRBS IN ONLINE MEDICAL RESEARCH 
Some commentators may argue that the problems raised by online research 
could be assuaged by an Institutional Review Board (IRB) evaluation of the re-
search proposal.347  However, much of the research conducted online is not even 
reviewed by an IRB.348  Also, a growing body of literature suggests that IRBs 
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researchers can use it to reveal medical attributes based on web browsing history). 
 347. See Heidi Ledford, Death in Gene Therapy Trial Raises Questions About Private IRBs, 25 NAT. 
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GOV’T ACCOUNTABILITY OFF., HUMAN SUBJECTS RESEARCH: UNDERCOVER TESTS SHOW THE 
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2009) (explaining the importance of the IRB review board in their role of assuring patient safety and trial 
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 348. See John Carberry, Media Statement on Cornell University’s Role in Facebook ‘Emotional Con-
tagion’ Research, CORNELL U. MEDIA REL. OFF. (June 30, 2014), http://mediarelations.cor-
nell.edu/2014/06/30/media-statement-on-cornell-universitys-role-in-facebook-emotional-contagion-re-
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research that would require review by the Cornell Human Research Protection Program because he only 
had access to the aggregated results of the study, and not individual identifiable data); see also Inder M. 
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are not doing an appropriate job of assessing the risks associated with proposed 
research projects, assuring the attainment of adequate informed consent, and pro-
tecting subjects from the risks.349  Online clinical trials present additional chal-
lenges for IRBs since they involve new processes (such as use of online health 
information, electronic consent forms, and so forth) that have not been specifi-
cally addressed in the federal research regulations that IRBs are supposed to fol-
low.350  In addition, IRBs may not appreciate the novel types of harms presented 
by online recruitment, especially given the lack of transparency about data col-
lection and use.351 
There are two types of IRBs.  Traditional, not-for-profit IRBs are generally 
based at research institutions352 and universities.353  However, in the past these 
traditional IRBs were unable to keep up with the increasing number of research 
trial proposals resulting from an exponential growth in biotechnological and 
pharmaceutical innovations,354 thus opening the door to private, for-profit IRBs 
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 350. See Stephanie Harriman & Jigisha Patel, The Ethics and Editorial Challenges of Interest-Based 
Research, 12 BMC MED. 124 (July 15, 2014), http://bmcmedicine.biomedcentral.com/arti-
cles/10.1186/s12916-014-0124-3 (noting that there is a lack of national standards for IRBs regarding in-
ternet based research in the UK and USA); see also CONSIDERATIONS AND RECOMMENDATIONS 
CONCERNING INTERNET RESEARCH AND HUMAN SUBJECTS RESEARCH REGULATIONS, WITH REVISIONS, 
SEC’Y’S ADVISORY COMM. ON HUM. RES. PROTS., HEALTH & HUM. SERVS, at 14 (2013) (recommending 
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 351. FTC, DATA BROKERS: A CALL FOR TRANSPARENCY AND ACCOUNTABILITY 57 (2015) (reporting 
that overall transparency in the data collection industry is lacking and making recommendations to en-
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 352. See Ledford, supra note 347, at 1067. 
 353. U.S. GOV’T ACCOUNTABILITY OFF., supra note 347, at 1. 
 354. See Obasogie, supra note 47 at 72–73 (discussing that there were approximately six times more 
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to fill in the demand for faster review and approval of studies.355  These private 
IRBs are organized either independently to review research studies or function 
within private companies to review the companies’ own research studies.356  Re-
search trials in traditional academic settings are now a minority when compared 
to the growing number of trials in private pharmaceutical companies.357  
Despite the crucial function that IRBs could play in protecting human re-
search subjects, scholars have criticized both the traditional and external IRB 
models as inadequate to ensure that research participants are adequately pro-
tected.358  On one hand, traditional IRBs are generally situated in the same re-
search institution as the studies that are being conducted.359  Therefore, the re-
searchers’ colleagues are often sitting on the IRB and are responsible for 
approving or denying the studies.360  This raises the issue of whether or their 
evaluations of studies are impartial.361  Similarly, an IRB that is funded by a 
private company conducting a research study necessarily has an interest in mak-
ing sure that studies are approved in order to increase profits.362  Even when 
reviewing studies for another entity, for-profit IRBs are interested in approving 
research quickly because for them it is a business transaction with the researchers 
conducting the study.363 
Scandals and investigations surrounding the inadequacy of the IRB model 
have surfaced regarding both for-profit and traditional IRBs.364  Prestigious re-
search institutions have had their studies and IRBs shut down due to gross inad-
equacies and lack of compliance with the relevant regulations.365  Investigative 
 
 355. See Ledford, supra note 347, at 1068 (addressing that researchers who also serve on non-profit 
IRB boards are evaluating their colleagues’ research protocols which may increase the likelihood that they 
will not perform critical evaluations).  
 356. Emanuel et al., supra note 349, at 942.  
 357. See id. (explaining that between 1994 and 2004, the number of clinical research trials conducted 
in a traditional academic setting decreased from 63% to 26%). 
 358. See id. at 941 (explaining that not for profit IRBs are also subject to conflicts of interest that may 
compromise the integrity of their evaluation); see also U.S. GOV’T ACCOUNTABILITY OFF., supra note 
347 at 1 (investigating the IRB system and finding that independent IRBs are subject to unethical manip-
ulation). 
 359. See Emanuel et al., supra note 349, at 941; see also Institutional Review Boards Frequently Asked 
Question—Information Sheet, FDA (Jan. 25, 2016), http://www.fda.gov/RegulatoryInformation/Guid-
ances/ucm126420.htm.  
 360. Emanuel et al., supra note 349, at 941. 
 361. Id. 
 362. See id. at 942 (explaining that commercial IRBs have a financial interest in approving trials, 
creating a conflict of interest); see also Ledford, supra note 347,  at 1067 (raising the concern of a system 
in which the regulated is the sole funder of its regulator and the regulated has the power to change its 
committee members to approve protocols to please customers). 
 363. Emanuel et al., supra note 349, at 942.  
 364. Id. at 942; Ledford, supra note 347. 
 365. See Emanuel et al., supra note 349, at 942 (discussing research institutions whose IRBs were shut 
down after the death of research participants); see also Ledford, supra note 347, at 1067 (discussing non-
profits such as Hopkins, Duke, and the University of Colorado that have had their IRBs shut down). 
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groups have been able to submit and obtain IRB approval for fake research stud-
ies purposely designed as posing a potential safety threat to research partici-
pants.366  
Because of the problems inherent in the current IRB model, it is questiona-
ble whether IRBs can truly ensure the protection of research subjects in virtual 
clinical trials. The Mytrus REMOTE trial underwent the review of two IRBs, 
one a traditional academic IRB at the University of California, San Francisco 
(UCSF) and the other a for-profit IRB, Western IRB (WIRB). 367  However, it is 
questionable whether they were able to adequately protect the REMOTE subjects 
due to the issues commonly associated with IRBs and the novel nature of online 
trials.  For example, WIRB’s history of approving risky studies is troubling.368  
Although UCSF’s IRB was also involved in the review and approval process, it 
is questionable whether its faster-than-usual approval process could have truly 
taken into consideration all of the factors at play in the risk-benefit analysis and 
protection of research subjects in a trial with unprecedented methodology.369 
With scholars questioning the adequacy of the current IRB model to review 
and approve traditional studies, it is unlikely that the added challenges to subject 
protection inherent in the online research model will be given the consideration 
they should receive when deciding to approve a study. In addition to the chal-
lenges posed by subjects being absent from a physical trial site—which could, 
for example, provide immediate medical assistance in case of an adverse reaction 
to a trial drug—the IRBs are ill-equipped to deal with the issues of electronic 
informed consent, as well as the increased threats to privacy and confidentiality 
of information arising from the online setting.370 
IX. RECOMMENDATIONS 
Virtual clinical trials present risks to participants and to the research pro-
cess. Given the risks, several policy changes should be made. 
 
 366. See generally U.S. GOV’T ACCOUNTABILITY OFF., supra note 347.  
 367. Lisa Henderson, An Idea Whose Time Came: Patient-Facing Clinical Trials Are Finally Imple-
mented a Decade Later http://www.appliedclinicaltrialsonline.com/idea-whose-time-came (last visited 
Sept. 10, 2016). 
 368. See, e.g., Evans et al., supra note 213, at 39, 54, 56 (documenting WIRB’s accountability for 
approving trials in which physicians were convicted in criminal investigations for putting the lives of 
research subjects in danger and for making false statements to the FDA); see also Ledford, supra note 
347, at 1067 (noting that bioethicists were concerned about WIRB following the death of a research par-
ticipant in a WIRB approved trial). 
 369. See Henderson, supra note 367. In an interview, then Mytrus’ Chief Operating Officer, Anthony 
Costello, explained that the approval process for the trial was rather fast, despite the amount of information 
the IRBs had to review, and despite the fact that IRBs usually operate slowly. Id. 
 370. James C. Hamilton, The Ethics of Conducting Social Science Research on the Internet, 46 
CHRON. HIGHER EDUC. B6 (1999) (reporting that many IRBs had reviewed proposals for online research 
but few of them had guidelines or the technical knowledge necessary to evaluate the proposals properly). 
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A. Online Health Information Should Be Treated as Confidential 
Confidentiality laws should be adopted by the states to ban the unauthorized 
collection, marketing or use of health information that a person discloses on the 
web.  The federal regulations adopted under HIPAA, should be extended simi-
larly to cover any online health information, even if it is not in the hands of a 
health care provider or a health care institution. 
B.  Recruitment Should Be Exclusively Consumer-Initiated 
Authorization for participation in research should be by an explicit opt-
in.371  Recruitment for medical research should not be based on health infor-
mation revealed through a person’s online activities or the imputation of health 
status through non-health data (such as posting about going to fast food restau-
rants or watching cable television).  Instead, a clinical trial website should be 
created that people can go to on their own to express interest in receiving infor-
mation about clinical trials, including virtual clinical trials.  In order to strike a 
balance with researcher’s legitimate need to enroll subjects into research trials, 
models such as the one developed by TrialX (where people can use Twitter to 
indicate that they would like to receive information about clinical trials) would 
be acceptable.372  
Furthermore, people who wish to keep their medical conditions confidential 
should not be subject to the anxiety-inducing process of suddenly being solicited 
for a virtual or in-person clinical trial for those medical conditions.373  Therefore, 
the Federal Trade Commission should investigate more broadly instances of un-
solicited recruitment for studies through the surreptitious collection of people’s 
medical information and consider the marketing of health information or inferred 
health status a form of consumer fraud.  
C.  Researchers Should Be Treated as Fiduciaries of Research Subjects 
Research subjects in virtual clinical trials currently lack the legal protec-
tions afforded to subjects in traditional research trials conducted by doctors in 
 
 371. Research suggests that people are largely in favor of an opt-in consent process, for example in 
research undertaken on biobank samples. See Christian M. Simon et al., Active Choice but Not Too Active: 
Public Perspectives on Biobank Consent Models, 13 GENETICS IN MED. 821, 826 (2011) (presenting a 
survey that found that a majority of focus group participants preferred an opt-in method).  
 372. @TrialX, TWITTER, https://twitter.com/trialx (last visited Dec. 9, 2016); see also A New Twitter 
Application by TrialX Lets You Find Clinical Trials That Match Your Health Conditions, FIERCE BIOTECH 
(Apr. 24, 2009, 10:16 am), http://www.fiercebiotech.com/biotech/a-new-twitter-application-by-trialx-
lets-you-find-clinical-trials-match-your-health. 
 373. See StopCorp.Crap, Comment to Acurian, Inc: Unsolicited Mail, COMPLAINTS BOARD, 
http://www.complaintsboard.com/complaints/acurian-inc-pennsylvania-c574582.html (last visited Jan. 
22, 2017) (showing examples of solicitation from clinical trials to persons who did not know that their 
medical conditions, or their child’s medical conditions, were known). 
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medical institutions.374  This could be addressed by a legal policy holding re-
searchers to be fiduciaries.  Researchers have several things in common with 
doctors which would justify considering them fiduciaries.375  Those factors in-
clude the research subject’s ignorance of the research and their need to entrust 
their well-being to researchers, the researcher’s superior knowledge of the sub-
ject matter and the consequences of research,376 and the fact that the research 
subject may consider his or her relationship with the researcher the same as that 
of his or her relationship with a doctor.377  Holding researchers to be fiduciaries 
would allow subjects to have legal recourse against researchers on a fiduciary 
duty basis, for example, as a result of harm caused to the subject from his or her 
participation in an unduly risky virtual clinical trial.378 
D.  The Electronic Informed Consent Process Should Include Additional 
Information and Safeguards 
Electronic informed consent should not be used without access to a person 
to answer questions.  In addition, the process should have a means of assuring 
the identity of the person who is signing the form and also of the person partici-
pating in the study. 
The consent process should also provide the subject with the ability to limit 
the sharing of information gathered from the study.  Electronic informed consent 
forms should give subjects full control over the sharing of study data, that is, 
whether they want their data to be used only by the researchers conducting the 
 
 374. U.S. DEPT. HEALTH & HUMAN SERV., SEC’Y’S ADVISORY COMM. ON HUMAN RESEARCH PROT., 
supra note 147 (recommending revisions to the federal regulations because they do not adequately address 
internet research issues); see also Valerie Gutmann Koch, A Private Right of Action for Informed Consent 
in Research, 45 SETON HALL L. REV. 173, 176 (2015) (stating that research subjects often do not have a 
private right of action because most jurisdictions do not recognize a legal relationship between the re-
searcher and the research subject). 
 375. See Richard S. Saver, Medical Research and Intangible Harm, 74 U. U. CIN. L. REV. 941, 990, 
(2006); see also Andrew Fichter, The Law of Doctoring: A Study of the Codification of Medical Profes-
sionalism, 19 HEALTH MATRIX: J. L.-MED. 317, 365–368 (2009) (arguing that researchers owe fiduciary 
duties to their subjects in a way that is similar to what is required of a doctor); see also Paul B. Miller & 
Charles Wijer, Fiduciary Obligation in Clinical Research, 34 J. MED. & ETHICS 424, 424, 428, 437 (2006) 
(arguing that the researcher-subject relationship should be considered fiduciary as a matter of law). 
 376. See Fichter, supra note 375, at 367 (stating the gap in knowledge investigators and participants 
possess inevitably exists, and that participants should not be responsible for their own protection).  
Whereas some legal commentators argue that researchers should be held to owe fiduciary duties to re-
search subjects, other legal scholars are more skeptical, arguing that fiduciary duties are not compatible 
with the need for researchers to adhere to the research protocol; see, e.g., E. Haavi Morreim, The Clinical 
Investigator as Fiduciary: Discarding a Misguided Idea, 33 J.L. MED. & ETHICS 586, 588 (2005) (main-
taining that researchers are not fiduciaries, as many research trials do not involve medical care and each 
role in research must be individually considered). 
 377. See Saver, supra note 375, at 941–1012, 967–71, 990–92. 
 378. See Moore v. Regents of the Univ. of Cal., 793 P.2d 479, 483 (Cal. 1990) (finding that the doctor-
researcher breached his fiduciary duty patient-participant and holding the doctor liable). 
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study, or if they would also consent to the use of their data in an additional spe-
cific study that is explained in detail.379  There should be no blanket consent for 
unspecified future research.  
Informed consent policies for virtual clinical trials should also address the 
issues of data security inherent when conducting the clinical trial process entirely 
online and should disclose to subjects the consequences that can result from a 
data breach.  It should clearly inform the subject of the potential issues that can 
arise as a result of the use of trial drugs—regardless of whether such drugs had 
been previously approved for the same or another condition.  
E.  Data Security Measures Should Be Taken by Virtual Clinical Trial 
Developers to Ensure the Protection of Sensitive Metrics and Personal 
Information of Research Participants 
Not only is medical information collected, but some medical apps used in 
research can turn on a subject’s microphone and track geolocation.380  As virtual 
clinical trials adopt smartphone platforms, more sensitive information about re-
search subjects will be collected, demanding strict data security protocols.381 
F. Drugs Should Not Be Approved Based Only on the Results of a Virtual 
Clinical Trial 
Because the virtual clinical trial’s data is self-reported, there is no way to 
assure the accuracy of such data.  Even the inventors who patented the virtual 
clinical trial process believe that “the internet based trial method is most suitable 
when the intervention is safe, the medical disorder can be confirmed by remote 
means and the outcome measures can be applied by using electronically trans-
missible technologies.”382  Also, to prevent potentially dangerous drugs from en-
tering the market, some type of in-person clinical trial should follow the virtual 
clinical trial to validate the virtual trial’s results.  
 
 379. Sage Bionetworks has developed an electronic informed consent form for ResearchKit’s mPower 
Parkinson’s disease app for iPhone. Although the app has an option for the sharing of study data with 
“Sage Bionetworks and its partners and qualified researchers worldwide” or to “only share [the] data with 
Sage Bionetworks and its partners” it does not specify who the partners are (their affiliations, whether 
they have any financial interests in the study, etc.) and it does not provide for an option to only let the 
researcher conducting the study (Sage Bionetworks) use the data. See Brian M. Bot et al., The mPower 
Study, Parkinson Disease Mobile Data Collected using ResearchKit, 3 SCIENTIFIC DATA 1, 2 (2016), 
http://doi.org/10.1038/sdata.2016.11. 
 380. See Blenner et al., supra note 113, at 1051 (reporting the results of a study that found that some 
diabetes apps could activate the microphone, track locations, and turn on the camera). 
 381. See id. (stating that the sharing of sensitive information from most medical apps is not currently 
prohibited by the Health Insurance Portability and Accountability Act). 
 382. McAlindon et al., supra note 65 at 487. 
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G.  IRBs Should Be Given Explicit Directives in the Federal Research 
Regulations for Dealing with Virtual Clinical Trials 
As technology changes the way in which research is conducted, IRB over-
sight will have to be implemented in a way that addresses novel challenges—
such as the need for proper identification of the user-subject and protecting the 
confidentiality of the electronic data, and ensuring that subjects’ health will be 
protected.  In addition, IRBs should be required to analyze whether privacy has 
been breached in recruitment or data analysis and to determine that adequate 
measures have been taken to protect cyber-security.  The IRBs should also be 
trained to recognize the novel psychological, physical and financial risks posed 
by virtual clinical trials. 
H. Any Federal or State Law Protecting Subjects in Virtual Clinical Trials 
Should Include a Private Cause of Action 
The current federal research regulations do not provide a private cause of 
action, thwarting recourse for even egregious violation of the regulations.383  A 
preferable model could be the California approach which gives research subjects 
the possibility of suing for violation of law regulating research, including inade-
quate informed consent.384 
X. CONCLUSION 
The purpose of research regulations is to: (1) protect people’s choice of 
whether or not to participate in research; (2) assure that subjects will not be 
harmed by the research and that the benefits outweigh the risks; (3) protect re-
search subjects’ confidentiality; (4) protect the public by assuring that the re-
search is adequate; and (5) ensure trust in the research enterprise so that people 
will continue to participate in research. However, the current conduct of online 
researchers fails to meet these goals and instead circumvents the very protection 
the regulations were meant to offer.  Informed consent is likely to be overlooked 
and is difficult to obtain in the online setting, privacy is likely to be breached, 
and the study methodologies may not adequately assure the safety of treatments 
investigated in the digital milieu. 
The internet has transformed relationships and social institutions in pro-
found ways.  Dating, education, marketing, and communicating are all stun-
ningly different in the post-Facebook era than they were a decade ago.  Physi-
cians, pharmaceutical companies, and biotechnology companies are all taking 
 
 383. See 45 C.F.R. § 46.113 (1991) (stating that violation of the regulations warrants suspension of 
institutional review board approval rather than a private cause of action for the research subjects).  
 384. In California, the Protection of Human Subjects in Medical Experimentation Act makes research-
ers who conduct research on human subjects without informed consent liable to the subjects for damages. 
CAL. HEALTH & SAFETY CODE § 24176 (West 2003). 
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advantage of social networks and the web to pursue online medical research.385  
Such research has risks as well as benefits, and it is important to employ tradi-
tional research protections for prior review, voluntary and un-coerced consent, 
assurances that the benefits of the research outweigh the risks, and protection of 
confidentiality. 
 
 
 385. See Allison, supra note 9, at 895 (detailing dozens of companies who are using social media to 
recruit patients and conduct clinical trials). 
